<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hydroxychloroquine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hydroxychloroquine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Hydroxychloroquine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11380" href="/d/html/11380.html" rel="external">see "Hydroxychloroquine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13366" href="/d/html/13366.html" rel="external">see "Hydroxychloroquine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F180857"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Plaquenil</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867144"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Hydroxyquine;</li>
<li>JAMP Hydroxychloroquine Sulf;</li>
<li>MINT-Hydroxychloroquine;</li>
<li>NRA-Hydroxychloroquine;</li>
<li>Plaquenil</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F180895"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Aminoquinoline (Antimalarial);</li>
<li>
                        Antimalarial Agent;</li>
<li>
                        Antirheumatic, Disease Modifying</li></ul></div>
<div class="block doa drugH1Div" id="F180861"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> To avoid retinopathy and permanent vision loss, do not exceed recommended maximum doses. Baseline and periodic screening for retinopathy is necessary for rheumatologic uses and in long-term therapy (eg, &gt;1 to 5 years depending on patient risk factors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26992838','lexi-content-ref-Travassos.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26992838','lexi-content-ref-Travassos.1'])">Ref</a></span>). To mitigate risk of cardiac arrhythmias, correct electrolyte imbalances prior to use.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> All doses below are expressed as hydroxychloroquine sulfate salt. <b>Hydroxychloroquine sulfate salt 200 mg is equivalent to hydroxychloroquine base 155 mg. </b>Variable daily dosing (eg, alternating or skipping doses on certain days each week) may be used to obtain the recommended dose for rheumatologic uses.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> In addition to administering with food or milk, to improve tolerability of the common adverse effect of GI upset (nausea, vomiting, diarrhea), may also administer at bedtime; for sarcoidosis and rheumatologic conditions, may divide doses, or gradually escalate the dose upon initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wallace.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wallace.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="047a4296-aea5-4cc5-9411-b3f5e9e00170">Dermatomyositis, cutaneous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dermatomyositis, cutaneous (off-label use): Note:</b> Used in combination with antipruritic medications, topical therapy, and nonpharmacologic measures (eg, photoprotection) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Targoff.1','lexi-content-ref-Vleugels.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Targoff.1','lexi-content-ref-Vleugels.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 300 to 400 mg daily as a single daily dose or in 2 divided doses. Assess response after 3 months; may attempt to slowly taper after several months of satisfactory response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16027300','lexi-content-ref-4093940','lexi-content-ref-Targoff.1','lexi-content-ref-Vleugels.1','lexi-content-ref-6715608']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16027300','lexi-content-ref-4093940','lexi-content-ref-Targoff.1','lexi-content-ref-Vleugels.1','lexi-content-ref-6715608'])">Ref</a></span>). <b>Note: </b>Due to the risk of retinal toxicity, most patients should <b>not</b> receive a daily dose &gt;5 mg/kg/day using actual body weight <b>or</b> 400 mg, whichever is lower (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26992838','lexi-content-ref-25275721','lexi-content-ref-31532077','lexi-content-ref-Wallace.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26992838','lexi-content-ref-25275721','lexi-content-ref-31532077','lexi-content-ref-Wallace.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="311fe009-0f2e-4adf-a04a-27361a619f87">Lupus erythematosus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lupus erythematosus:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Systemic lupus erythematosus: </i>
<b>Note: </b>In general, hydroxychloroquine (or chloroquine) is indicated for all patients with systemic disease; additional therapy is individualized according to predominant disease manifestations and activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27548593','lexi-content-ref-26479437','lexi-content-ref-Wallace.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27548593','lexi-content-ref-26479437','lexi-content-ref-Wallace.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 200 to 400 mg daily as a single daily dose or in 2 divided doses. <b>Note: </b>Due to the risk of retinal toxicity, most patients should <b>not</b> receive a daily dose &gt;5 mg/kg/day using actual body weight <b>or</b> 400 mg, whichever is lower (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26992838','lexi-content-ref-25275721','lexi-content-ref-31532077','lexi-content-ref-Wallace.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26992838','lexi-content-ref-25275721','lexi-content-ref-31532077','lexi-content-ref-Wallace.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Discoid lupus erythematosus and subacute cutaneous lupus erythematosus:</i> For use if response to local therapy is inadequate or impractical due to widespread skin lesions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Clarke.1','lexi-content-ref-27859683']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Clarke.1','lexi-content-ref-27859683'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 200 to 400 mg daily as a single daily dose or in 2 divided doses. <b>Note: </b>Due to the risk of retinal toxicity, most patients should <b>not</b> receive a daily dose &gt;5 mg/kg/day using actual body weight <b>or</b> 400 mg, whichever is lower (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26992838','lexi-content-ref-25275721','lexi-content-ref-31532077','lexi-content-ref-Wallace.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26992838','lexi-content-ref-25275721','lexi-content-ref-31532077','lexi-content-ref-Wallace.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0acddc60-f298-46aa-ab90-6ccb55be7fd5">Malaria</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malaria (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis:</i>
<b>Note:</b> Only for use in individuals traveling to malarious regions <b>without</b> chloroquine resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 400 mg once weekly on the same day each week; begin 1 to 2 weeks before travel to malarious area; continue therapy while in malarious area and for 4 weeks after leaving the area (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment, uncomplicated:</i>
<b>Note:</b> Only for treatment of nonsevere infections caused by chloroquine-sensitive malaria; for infection caused by <i>Plasmodium vivax</i> or <i>Plasmodium ovale</i>, give in combination with primaquine. Not recommended for treatment if chloroquine or hydroxychloroquine was given for chemoprophylaxis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2','lexi-content-ref-WHO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2','lexi-content-ref-WHO.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 800 mg once, followed by 400 mg at 6, 24, and 48 hours after initial dose (total dose: 2 <b>g</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2','lexi-content-ref-WHO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2','lexi-content-ref-WHO.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cd8de141-ef8a-4bae-aaa6-dce46617c97d">Porphyria cutanea tarda</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Porphyria cutanea tarda (off-label use):</b>
<b>Oral:</b> 100 mg <b>twice weekly</b>; continue until plasma or urine porphyrin levels are normal for at least several months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22985607','lexi-content-ref-Singal.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22985607','lexi-content-ref-Singal.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f2f944b9-4cf2-4dce-89fb-58b40ac6d63d">Primary Sjögren disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary Sjögren disease (off-label use):</b>
<b>Note: </b>For treatment of moderate to severe extraglandular manifestations (eg, arthralgias, myalgias, fatigue) or milder symptoms unresponsive to nonpharmacologic measures and nonsteroidal anti-inflammatory drugs (NSAIDs) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27390247','lexi-content-ref-28913747','lexi-content-ref-8803908','lexi-content-ref-8323383','lexi-content-ref-16932698']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27390247','lexi-content-ref-28913747','lexi-content-ref-8803908','lexi-content-ref-8323383','lexi-content-ref-16932698'])">Ref</a></span>); some experts also use in patients with major salivary enlargement resulting in cosmetic concerns or glandular pain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baer.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 200 to 400 mg daily as a single daily dose or in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25027140','lexi-content-ref-8323383','lexi-content-ref-16932698']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25027140','lexi-content-ref-8323383','lexi-content-ref-16932698'])">Ref</a></span>). <b>Note: </b>Due to the risk of retinal toxicity, most patients should <b>not</b> receive a daily dose &gt;5 mg/kg/day using actual body weight <b>or</b> 400 mg, whichever is lower (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26992838','lexi-content-ref-25275721','lexi-content-ref-31532077','lexi-content-ref-Wallace.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26992838','lexi-content-ref-25275721','lexi-content-ref-31532077','lexi-content-ref-Wallace.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ee55d874-2d0b-4f70-bab7-3457c401ca26">Q fever</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Q fever (<i>Coxiella burnetii</i>) (off-label use): Note:</b> Given higher dose recommendations for Q fever, the CDC recommends routine therapeutic drug monitoring and ophthalmic exams for retinal toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23535757']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23535757'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Persistent localized infection (eg, endocarditis, osteoarticular infection, vascular infection) in nonpregnant patients</i>: <b>Oral:</b> 200 mg 3 times daily in combination with doxycycline for ≥18 to 24 months, depending on site of infection and serologic response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23535757']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23535757'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prevention of persistent infection following acute Q fever</i>: <b>Note: </b>Generally reserved for patients with valvulopathy/cardiomyopathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23535757','lexi-content-ref-23794723']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23535757','lexi-content-ref-23794723'])">Ref</a></span>) or postpartum women with persistent serologic evidence of infection &gt;12 months after delivery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23535757']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23535757'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 200 mg 3 times daily in combination with doxycycline for 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23535757','lexi-content-ref-23794723']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23535757','lexi-content-ref-23794723'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="32775de1-c27b-4d28-84e6-04adfdee9a40">Rheumatoid arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatoid arthritis: Note:</b> For use as monotherapy in disease-modifying antirheumatic drug (DMARD)–naive patients with low disease activity. May also be used as part of alternative combination therapy (with other nonbiologic DMARDs) in patients with moderate to severe disease whose treatment targets have not been met despite maximally tolerated methotrexate therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34101387','lexi-content-ref-31969328','lexi-content-ref-23997576','lexi-content-ref-23755969','lexi-content-ref-21044434','lexi-content-ref-27156434']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34101387','lexi-content-ref-31969328','lexi-content-ref-23997576','lexi-content-ref-23755969','lexi-content-ref-21044434','lexi-content-ref-27156434'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 200 to 400 mg daily as a single daily dose or in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23997576']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23997576'])">Ref</a></span>). <b>Note: </b>Due to the risk of retinal toxicity, most patients should <b>not</b> receive a daily dose &gt;5 mg/kg/day using actual body weight <b>or</b> 400 mg, whichever is lower (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26992838','lexi-content-ref-25275721','lexi-content-ref-31532077','lexi-content-ref-Wallace.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26992838','lexi-content-ref-25275721','lexi-content-ref-31532077','lexi-content-ref-Wallace.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f7b8bb7f-a3e8-40dc-9502-9d82651f5264">Sarcoidosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sarcoidosis (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Arthropathy: </i>
<b>Note: </b> As additional therapy for NSAID-resistant symptoms in patients with an inadequate response to glucocorticoids or who are unable to fully taper (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30187668','lexi-content-ref-Sequeira.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30187668','lexi-content-ref-Sequeira.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 200 to 400 mg daily as a single daily dose or in 2 divided doses. Therapy may be continued for ~1 year and then gradually tapered in patients who have responded and are stable on therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sequeira.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sequeira.2019'])">Ref</a></span>). <b>Note: </b>Due to the risk of retinal toxicity, most patients should <b>not</b> receive a daily dose &gt;5 mg/kg/day using actual body weight <b>or</b> 400 mg, whichever is lower (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26992838','lexi-content-ref-25275721','lexi-content-ref-31532077','lexi-content-ref-Wallace.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26992838','lexi-content-ref-25275721','lexi-content-ref-31532077','lexi-content-ref-Wallace.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cutaneous disease, extensive:</i>
<b>Oral:</b> 200 to 400 mg daily as a single daily dose or in 2 divided doses for ≥3 months to evaluate for efficacy; if there is satisfactory improvement, may consider gradual tapering and discontinuation if response is maintained (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18491485','lexi-content-ref-Prystowsky.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18491485','lexi-content-ref-Prystowsky.1'])">Ref</a></span>). <b>Note: </b>Due to the risk of retinal toxicity, most patients should <b>not</b> receive a daily dose &gt;5 mg/kg/day using actual body weight <b>or</b> 400 mg, whichever is lower (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26992838','lexi-content-ref-25275721','lexi-content-ref-31532077','lexi-content-ref-Wallace.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26992838','lexi-content-ref-25275721','lexi-content-ref-31532077','lexi-content-ref-Wallace.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991638"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Mild to severe impairment:</b> There are no specific dosage adjustments provided in the manufacturer's labeling; however, dosage reduction may be needed with prolonged use (eg, systemic lupus erythematosus) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7904547']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7904547'])">Ref</a></span>); use with caution. With short-term use at recommended doses and durations (eg, malaria treatment), no dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis:</b> Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25989906']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25989906'])">Ref</a></span>): There are no specific dosage adjustments provided in the manufacturer's labeling; however, dosage reduction may be needed with prolonged use (eg, systemic lupus erythematosus) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7904547']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7904547'])">Ref</a></span>); use with caution. With short-term use at recommended doses and durations (eg, malaria treatment), no dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> There are no specific dosage adjustments provided in the manufacturer's labeling; however, dosage reduction may be needed with prolonged use (eg, systemic lupus erythematosus) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7904547']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7904547'])">Ref</a></span>); use with caution. With short-term use at recommended doses and durations (eg, malaria treatment), no dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Unlikely to be dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32259313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32259313'])">Ref</a></span>): There are no specific dosage adjustments provided in the manufacturer's labeling; however, dosage reduction may be needed with prolonged use (eg, systemic lupus erythematosus) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7904547']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7904547'])">Ref</a></span>); use with caution. With short-term use at recommended doses and durations (eg, malaria treatment), no dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988931"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatotoxicity associated with porphyria cutanea tarda (off-label use) during therapy: Interrupt treatment if ALT &gt;3 times ULN and total bilirubin &gt;2 times ULN.</p></div>
<div class="block doo drugH1Div" id="F49056601"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Rheumatic diseases (eg, rheumatoid arthritis, lupus erythematosus, primary Sjögren disease [off-label use]):</b> Available data do not specifically address dosing in obese patients; however, some experts recommend standard daily doses (non-weight-based) up to a maximum of 400 mg/day in patients weighing ≥80 kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wallace.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wallace.1'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F180862"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F180880"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13366" href="/d/html/13366.html" rel="external">see "Hydroxychloroquine: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>To avoid retinopathy and permanent vision loss, do not exceed recommended maximum doses. Baseline and periodic screening for retinopathy is necessary for rheumatologic uses and in long-term therapy (eg, &gt;1 to 5 years depending on patient risk factors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26992838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26992838'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> All doses below expressed as hydroxychloroquine sulfate. <b>Hydroxychloroquine sulfate 200 mg is equivalent to 155 mg hydroxychloroquine base</b>.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0acddc60-f298-46aa-ab90-6ccb55be7fd5">Malaria</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malaria:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chemoprophylaxis:</i>
<b>Note:</b> Only for use in individuals traveling to malarious regions <b>without</b> chloroquine resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: Oral: 6.5 mg/kg hydroxychloroquine sulfate once weekly on the same day each week; maximum dose: 400 mg/dose hydroxychloroquine sulfate; begin 1 to 2 weeks before travel to malarious area; continue while in malarious area and for 4 weeks after leaving the area (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment, uncomplicated:</i> Infants, Children, and Adolescents: Oral: Initial: 12.9 mg/kg/dose hydroxychloroquine sulfate (maximum initial dose: 800 mg/dose hydroxychloroquine sulfate); followed by 6.5 mg/kg hydroxychloroquine sulfate at 6, 24, and 48 hours after initial dose; maximum dose: 400 mg/dose hydroxychloroquine sulfate. For infection caused by <i>Plasmodium vivax </i>or <i>Plasmodium</i>
<i> ovale</i>, use in combination with appropriate antirelapse treatment (ie, primaquine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="97241778-4354-4522-b35e-0d9b1f8d0681">Juvenile dermatomyositis, skin predominant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Juvenile dermatomyositis, skin predominant:</b> Limited data available: Children and Adolescents: Oral: 5 mg/kg/day in 1 to 2 divided doses; maximum daily dose: 400 mg/<b>day</b>. Dosage range reported: 2 to 6 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28077146','lexi-content-ref-Kliegman.1','lexi-content-ref-2483176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28077146','lexi-content-ref-Kliegman.1','lexi-content-ref-2483176'])">Ref</a></span>); however, some experts recommend a maximum of 5 mg/kg/<b>day</b> to mitigate risk of retinal toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26992838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26992838'])">Ref</a></span>). Use in combination with nonpharmacologic measures (eg, photoprotection), topical therapies, and/or other systemic therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28077146','lexi-content-ref-Kliegman.1','lexi-content-ref-2483176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28077146','lexi-content-ref-Kliegman.1','lexi-content-ref-2483176'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1bbd4868-9b68-4f56-a652-b28778790f81">Systemic lupus erythematosus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Systemic lupus erythematosus (SLE):</b> Limited data available: Children and Adolescents: 4 to 6.5 mg/kg/day in 1 to 2 divided doses; maximum daily dose: 400 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30926722','lexi-content-ref-20222881','lexi-content-ref-26971103']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30926722','lexi-content-ref-20222881','lexi-content-ref-26971103'])">Ref</a></span>); based upon data in adults, some experts recommend a maximum of 5 mg/kg/<b>day</b> to mitigate risk of retinal toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26992838','lexi-content-ref-Costedoat.1','lexi-content-ref-30926722','lexi-content-ref-31201171']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26992838','lexi-content-ref-Costedoat.1','lexi-content-ref-30926722','lexi-content-ref-31201171'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51113367"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b>Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Renal clearance accounts for 15% to 25% of total clearance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7904547']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7904547'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Mild to severe impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Dosage adjustment may be considered with chronic use.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis: </b>Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25989906']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25989906'])">Ref</a></span>): There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Dosage adjustment may be considered with chronic use.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Dosage adjustment may be considered with chronic use.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous renal replacement therapy (CRRT):</b> Unlikely to be dialyzable based on wide volume of distribution and high lipophilicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32259313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32259313'])">Ref</a></span>): There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Dosage adjustment may be considered with chronic use.</p></div>
<div class="block dohp drugH1Div" id="F51113368"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block arsc drugH1Div" id="F54441455"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiomyopathy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">A predominantly restrictive or diastolic <b>cardiomyopathy</b> presenting as heart failure has been reported following long-term use of antimalarials for rheumatic diseases (especially chloroquine but occasionally hydroxychloroquine); systolic impairment may also occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27400984','lexi-content-ref-32725108','lexi-content-ref-24062937','lexi-content-ref-22550010','lexi-content-ref-23635029']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27400984','lexi-content-ref-32725108','lexi-content-ref-24062937','lexi-content-ref-22550010','lexi-content-ref-23635029'])">Ref</a></span>). Additionally, conduction abnormalities (eg, <b>atrioventricular block, sick sinus syndrome, bundle branch block</b>) and <b>pulmonary hypertension</b> have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23154245','lexi-content-ref-17202178','lexi-content-ref-32725108','lexi-content-ref-22550010','lexi-content-ref-23635029']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23154245','lexi-content-ref-17202178','lexi-content-ref-32725108','lexi-content-ref-22550010','lexi-content-ref-23635029'])">Ref</a></span>). On imaging, myocardial hypertrophy is most common in patients who develop cardiomyopathy. Clinicians should note that some patients may not have any or very few clinical symptoms. Laboratory findings may include elevated creatine kinase, lactate dehydrogenase, and/or troponins (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27400984','lexi-content-ref-22550010','lexi-content-ref-23635029']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27400984','lexi-content-ref-22550010','lexi-content-ref-23635029'])">Ref</a></span>). While some patients may experience improvement following discontinuation, others experience permanent damage that may result in the need for cardiac transplant or death (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27400984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27400984'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Time-related; exact mechanism is unknown. Hydroxychloroquine is hypothesized to bind to phospholipids within the myocyte, leading to accumulation in lysosomes and inhibiting lysosomal enzymes in several tissues, including peripheral nerve, cardiac, and skeletal muscle. The resulting intracellular degradation leads to accumulation of metabolic products (eg, phospholipids, glycogen) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18720511','lexi-content-ref-27400984','lexi-content-ref-22550010','lexi-content-ref-23635029']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18720511','lexi-content-ref-27400984','lexi-content-ref-22550010','lexi-content-ref-23635029'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Delayed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27400984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27400984'])">Ref</a></span>); patients may remain clinically asymptomatic for a long period of time with symptoms only appearing at a later stage and/or with high cumulative doses (eg, several years of therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23635029']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23635029'])">Ref</a></span>). Some patients may experience improvement within 1 month to 1 year following discontinuation, others experience permanent damage that may result in the need for cardiac transplant or death (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27400984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27400984'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">The following confers an increased risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32236844','lexi-content-ref-23635029','lexi-content-ref-22550010']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32236844','lexi-content-ref-23635029','lexi-content-ref-22550010'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">• Longer duration of therapy</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher cumulative doses</p>
<p style="text-indent:-2em;margin-left:8em;">• Older age</p>
<p style="text-indent:-2em;margin-left:8em;">• Females</p>
<p style="text-indent:-2em;margin-left:8em;">• Preexisting cardiac disease</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">G6PD deficiency</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Although the manufacturer's labeling recommends that hydroxychloroquine be used with caution in patients with glucose-6-phospate deficiency (G6PD) due to the potential for <b>hemolysis</b> (hemolytic anemia), there are limited data to support this risk. Many experts consider hydroxychloroquine, when given in usual therapeutic doses to WHO Class II and III G6PD deficient patients, to probably be safe (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18177777','lexi-content-ref-27040960','lexi-content-ref-20701405']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18177777','lexi-content-ref-27040960','lexi-content-ref-20701405'])">Ref</a></span>). In a retrospective chart review, no incidence of hemolytic anemia was found among the 11 patients identified with G6PD deficiency receiving hydroxychloroquine therapy, despite &gt;700 months of exposure (all patients were African-American and located in the US) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28556555']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28556555'])">Ref</a></span>). In addition, the ACR Rheumatology guidelines do not mention the need to evaluate G6PD levels prior to initiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26545940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26545940'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cutaneous hypersensitivity reactions ranging from maculopapular rash to severe cutaneous adverse reactions (SCARs) may occur. Various delayed, nonlife-threatening reactions have been reported, including lichenoid, urticarial, and maculopapular eruptions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31085265','lexi-content-ref-32289395','lexi-content-ref-26457932']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31085265','lexi-content-ref-32289395','lexi-content-ref-26457932'])">Ref</a></span>). Reported SCARs include <b>acute generalized exanthematous pustulosis </b>(AGEP), <b>drug reaction with eosinophilia and systemic symptoms </b>(DRESS [also known as drug hypersensitivity syndrome]), <b>Stevens-Johnson syndrome </b>(SJS), and <b>toxic epidermal necrolysis </b>(TEN) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26729969','lexi-content-ref-29186260','lexi-content-ref-19727917','lexi-content-ref-11961185','lexi-content-ref-32289395','lexi-content-ref-17952481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26729969','lexi-content-ref-29186260','lexi-content-ref-19727917','lexi-content-ref-11961185','lexi-content-ref-32289395','lexi-content-ref-17952481'])">Ref</a></span>). Hydroxychloroquine is also associated with phototoxic and photoallergic dermatitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26457932']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26457932'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non-dose related; immunologic; delayed hypersensitivity reactions are mediated by T-cells or antibodies other than immunoglobulin E (IgE) (eg, IgG-mediated, such as some cytopenias) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>). SCARs are delayed type IV hypersensitivity reactions involving a T-cell mediated drug-specific immune response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; most nonlife-threatening cutaneous reactions occurred 5 to 14 days after initiation of hydroxychloroquine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31085265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31085265'])">Ref</a></span>). Onset of SCARs is generally days to weeks after administration of the causative drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24138979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24138979'])">Ref</a></span>) but may occur more rapidly (usually within 1 to 4 days) upon reexposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.2014'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i> Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Prior hypersensitivity reaction to 4-aminioquinolines. <b>Note: </b>There is conflicting evidence regarding cross-reactivity between the 4-aminoquinolines (eg, chloroquine, hydroxychloroquine), although most reports suggest tolerance of chloroquine in patients with nonsevere cutaneous reactions to hydroxychloroquine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12224986','lexi-content-ref-30758479','lexi-content-ref-26457932']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12224986','lexi-content-ref-30758479','lexi-content-ref-26457932'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with dermatomyositis, in particular those with anti-small ubiquitin-like modifier 1 activating enzyme (anti-SAE-1/2) autoantibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30140893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30140893'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypoglycemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Severe hypoglycemia</b> has rarely been reported in patients (both with and without diabetes) who were receiving hydroxychloroquine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18222983','lexi-content-ref-9918262','lexi-content-ref-21169846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18222983','lexi-content-ref-9918262','lexi-content-ref-21169846'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; related to the pharmacologic action. Chloroquine has been shown to reduce intracellular insulin degradation, increase intracellular insulin accumulation, slow receptor recycling, stimulate insulin-mediated glucose transport, and increase peripheral insulin sensitivity and secretion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18222983','lexi-content-ref-21169846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18222983','lexi-content-ref-21169846'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Unknown. In one case report, a patient was initiated on hydroxychloroquine and presented to the emergency department 2 months later with symptoms secondary to severe hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18222983']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18222983'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of other medications known to lower blood glucose concentrations</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuromuscular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Skeletal muscle<b> myopathy</b> or neuropathy leading to asthenia and atrophy of proximal muscle groups, depressed tendon reflexes, and abnormal nerve conduction have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18720511','lexi-content-ref-16096334']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18720511','lexi-content-ref-16096334'])">Ref</a></span>). Symptoms ranged from painless proximal weakness in both upper and lower extremities to severe weakness requiring hospitalization and ventilatory support (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18720511','lexi-content-ref-16096334']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18720511','lexi-content-ref-16096334'])">Ref</a></span>). Clinicians should note that patients with rheumatic disease may experience symptoms of their underlying disease that make diagnosis of myopathy difficult (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16096334']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16096334'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Time-related; exact mechanism is unknown. Hydroxychloroquine is hypothesized to bind to phospholipids within the myocyte, accumulating in lysosomes and inhibiting lysosomal enzymes in several tissues, including peripheral nerve, cardiac, and skeletal muscle. The resulting intracellular degradation leads to accumulation of metabolic products (eg, phospholipids, glycogen) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18720511','lexi-content-ref-27400984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18720511','lexi-content-ref-27400984'])">Ref</a></span>). Muscle and nerve biopsies have been associated with curvilinear bodies and muscle fiber atrophy with vacuolar changes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3826099']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3826099'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Delayed; varies from &lt;1 year of therapy to &gt;10 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3826099']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3826099'])">Ref</a></span>). In addition, the response to discontinuation of hydroxychloroquine varies with some patients experiencing resolution of symptoms within weeks to months while others experience progression of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7704464','lexi-content-ref-16096334','lexi-content-ref-3826099']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7704464','lexi-content-ref-16096334','lexi-content-ref-3826099'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Risk factors are poorly defined but may include:</p>
<p style="text-indent:-2em;margin-left:8em;">• White people (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18720511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18720511'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18720511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18720511'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant use of other myotoxic drugs, including corticosteroids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18720511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18720511'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuropsychiatric effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Various neuropsychiatric effects have been reported with antimalarial agents, including hydroxychloroquine, in patients with and without a history of psychiatric disorders. Effects include <b>agitation, anxiety, delusion</b>, <b>depression, hallucination, mania, paranoid ideation,</b>
<b>psychosis</b>, <b>psychomotor agitation</b>, <b>sleep disorders (insomnia, night terrors, nightmares), suicidal ideation</b>, and <b>suicidal tendencies</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24268495','lexi-content-ref-28258476','lexi-content-ref-29948492','lexi-content-ref-23829886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24268495','lexi-content-ref-28258476','lexi-content-ref-29948492','lexi-content-ref-23829886'])">Ref</a></span>). One case report of neuropsychiatric effects following use of chloroquine demonstrated that effects may persist for several months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15728331']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15728331'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Time-related; exact mechanism is not fully understood. Proposed hypotheses include a cholinergic imbalance related to the inhibition of the acetylcholinesterase, prostaglandin E antagonism, the accumulation of toxic metabolites in the lysosome, and the down-regulation of glycoprotein-P in the blood brain barrier (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24268495']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24268495'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Intermediate; typically occurs within the first month after initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of neuropsychiatric effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29948492']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29948492'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Female patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29948492']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29948492'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent medications known to increase hydroxychloroquine concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29948492']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29948492'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29948492']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29948492'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent alcohol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29948492']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29948492'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Low body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29948492']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29948492'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">QT prolongation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Long-term use or high doses of antimalarials (especially chloroquine but also hydroxychloroquine) have been associated with <b>prolonged QT interval on ECG </b>and subsequent <b>ventricular arrhythmias </b>(including <b>torsades de pointes</b> [TdP]), syncope, and sudden cardiac death (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29858838','lexi-content-ref-16615675','lexi-content-ref-17590456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29858838','lexi-content-ref-16615675','lexi-content-ref-17590456'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; exact mechanism is unknown. Hydroxychloroquine is hypothesized to abnormally affect ion currents (including hyperpolarization activated ion channels, delayed rectifier potassium currents, and L-type calcium ion currents). This may cause delayed depolarization and prolonged repolarization of cardiac myocytes, which can lead to QT interval prolongation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27478650']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27478650'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; effect is concentration-dependent; therefore, timing may be impacted by high doses or accumulation. In one study in healthy subjects administered chloroquine (100 mg base per day; n=3), QT prolongation was noted on day 3 of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7939166']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7939166'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">In general, risk factors for drug-induced QT prolongation include:</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-WHO.2017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-WHO.2017'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Structural heart disease (eg, history of myocardial infarction or heart failure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-WHO.2017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-WHO.2017'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Genetic defects of cardiac ion channels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-WHO.2017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-WHO.2017'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Congenital long QT syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-WHO.2017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-WHO.2017'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Baseline QTc interval prolongation (eg, &gt;450 msec) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Electrolyte disturbances (eg, hypokalemia or hypomagnesemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-WHO.2017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-WHO.2017'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-WHO.2017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-WHO.2017'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-WHO.2017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-WHO.2017'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Coadministration of multiple medications that prolong the QT interval or drug interactions that increase serum concentration of QT-prolonging medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-WHO.2017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-WHO.2017'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Retinal toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Long-term use of hydroxychloroquine may result in <b>retinopathy</b> characterized by parafoveal retinal damage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30401979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30401979'])">Ref</a></span>). The clinical picture is classically characterized as a bilateral “bull's-eye”<b> maculopathy</b>; visual acuity generally remains intact until more severe damage has been realized. As retinopathy progresses, the area of functional deficit may expand to the foveal center with <b>decreased visual acuity</b>, peripheral vision, and night vision; cystoid macular edema may also occur. Clinicians should note that some patients may not experience symptoms during the early stages of retinopathy and that retinopathy is irreversible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26992838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26992838'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Time-related; exact mechanism is not fully understood. A proposed mechanism is impaired lysosomal degradation of photoreceptor outer segments by the retinal pigment epithelium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30401979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30401979'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Delayed; most commonly occurring &gt;5 years after initiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26992838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26992838'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• High daily doses relative to body weight (≥5 mg/kg actual body weight) and a duration of &gt;5 years of use in the treatment of rheumatic diseases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26992838','lexi-content-ref-25275721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26992838','lexi-content-ref-25275721'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher serum concentrations of hydroxychloroquine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31532077']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31532077'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent tamoxifen use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26992838','lexi-content-ref-25275721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26992838','lexi-content-ref-25275721'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26992838','lexi-content-ref-25275721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26992838','lexi-content-ref-25275721'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Lower body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25275721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25275721'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting macular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26992838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26992838'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F180829"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Ophthalmic: Retinopathy (4%; serum concentration dependent [Petri 2020b]; early changes reversible [may progress despite discontinuation if advanced])</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Hematologic &amp; oncologic: Hemolysis (rare; primarily a theoretical concern in patients with glucose-6-phosphate deficiency; data do not support withholding therapy in these patients [Luzzato 2016; Mohammad 2018])</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Sick sinus syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Exacerbation of psoriasis, exfoliative dermatitis, hair discoloration, pruritus, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, anorexia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, aplastic anemia, bone marrow depression, leukopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia, dizziness, emotional lability, fatigue, headache, irritability, nervousness, seizure, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Corneal changes (corneal edema, corneal opacity), nystagmus disorder, ophthalmic signs and symptoms (decreased dark adaptation)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrioventricular block (Bae 2012), bundle branch block (Costedoat-Chalumeau 2007), cardiomyopathy (AHA [Page 2016]; Fiehn 2020; Tönnesmann 2012; Tönnesmann 2013), heart failure (Figliozzi 2021), prolonged QT interval on ECG (Chatre 2018; Chen 2006; O’Laughlin 2016; Stas 2008), torsades de pointes (Chatre 2018; O’Laughlin 2016), ventricular arrhythmia (Chatre 2018; O’Laughlin 2016), ventricular tachycardia (Abdelmaseih 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Charfi 2015; Soria 2015), alopecia (Sharma 2020), erythema multiforme (Abou Assalie 2017), erythroderma (Pai 2017), hyperpigmentation (Bahloul 2017; Sharma 2020), pustular psoriasis (Chen 2023), skin photosensitivity (Sharma 2020), skin rash (Borik 2019), Stevens-Johnson syndrome (Leckie 2002), toxic epidermal necrolysis (Lateef 2009; Soria 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoglycemia (including severe hypoglycemia; Cansu 2008; FDA Safety Alert, April 1, 2020; Shojania 1999; Unübol 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps (Abdelmaseih 2020), diarrhea (can be severe) (Abdelmaseih 2020), nausea (Abdelmaseih 2020), vomiting (Abdelmaseih 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Proteinuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Andrès 2017), neutropenia (FDA Safety Alert, April 1, 2020), pancytopenia (FDA Safety Alert, April 1, 2020), thrombotic thrombocytopenic purpura (Arikan 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Acute hepatic failure (Makin 1994)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Drug reaction with eosinophilia and systemic symptoms (Soria 2015; Volpe 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, anxiety, confusion (FDA Safety Alert, April 1, 2020), delirium (FDA Safety Alert, April 1, 2020), delusion, depression, extrapyramidal reaction (FDA Safety Alert, April 1, 2020), hallucination (Das 2014; FDA Safety Alert, April 1, 2020), mania, paranoid ideation, psychomotor agitation (FDA Safety Alert, April 1, 2020; Manzo 2017), psychosis (Das 2014), sleep disturbance (including insomnia, nightmares, night terrors), suicidal ideation (Mascolo 2018; Pinho de Oliveira Ribeiro 2013), suicidal tendencies (Mascolo 2018; Pinho de Oliveira Ribeiro 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myopathy (including paralysis or neuromyopathy, leading to progressive weakness and atrophy of proximal muscle groups; may be associated with mild sensory changes, loss of deep tendon reflexes, and abnormal nerve conduction; Casado 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (Wang 2021), corneal deposits (Grierson 1997), decreased visual acuity (Eldeeb 2018), epithelial keratopathy (Dosso 2007), macular degeneration (Wang 2021), maculopathy (Warner 2001), photophobia (Grierson 1997), retinal pigment changes (Stelton 2013), scotoma (Eldeeb 2018, Stelton 2013), vision color changes (Stelton 2013), visual disturbance (Grierson 1997), visual field defect (Warner 2001)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Sensorineural hearing loss (Fernandes 2018), tinnitus (Fernandes 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Kidney impairment (FDA Safety Alert, April 1, 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary hypertension (Bae 2012)</p></div>
<div class="block coi drugH1Div" id="F180842"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Known hypersensitivity to hydroxychloroquine, 4-aminoquinoline derivatives, or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Preexisting retinopathy; use in children &lt;6 years or weighing &lt;35 kg</p></div>
<div class="block war drugH1Div" id="F180826"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; dosage reduction may be needed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with caution in patients with myasthenia gravis; may exacerbate condition (Jallouli 2012; MGFA 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">• Porphyria: Avoid use in patients with porphyria unless benefits outweigh risks; may exacerbate or precipitate disease. Use in patients with porphyria cutanea tarda (off-label use) has resulted in hepatotoxicity and presented with marked elevations in transaminases within days to one month after initiation of treatment. In some patients, porphyria cutanea tarda was diagnosed after hepatotoxicity occurred when hydroxychloroquine was used for an approved indication.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psoriasis: Avoid use in patients with psoriasis unless benefits outweigh risks; may exacerbate or precipitate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage reduction may be needed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Glucose-6-phosphate dehydrogenase deficiency: Although the manufacturer's labeling recommends hydroxychloroquine be used with caution in patients with G6PD deficiency due to a potential for hemolytic anemia, there are limited data to support this risk. Many experts consider hydroxychloroquine, when given in usual therapeutic doses to the World Health Organization Class II and III G6PD deficient patients, to probably be safe (Cappellini 2008; Luzzatto 2016; Youngster 2010). In a retrospective chart review, no incidence of hemolytic anemia was found among the 11 patients identified with G6PD deficiency receiving hydroxychloroquine therapy, despite &gt;700 months of exposure (all patients were African American and located in the United States) (Mohammad 2018). In addition, the American College of Rheumatology guidelines for the treatment of rheumatoid arthritis do not mention the need to evaluate G6PD levels prior to initiation of therapy (ACR [Fraenkel 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Pediatric patients have an increased sensitivity to aminoquinolines.</p></div>
<div class="block foc drugH1Div" id="F180836"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Plaquenil: 200 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 200 mg, 300 mg, 400 mg</p></div>
<div class="block geq drugH1Div" id="F180822"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F180844"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Hydroxychloroquine Sulfate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $2.24 - $2.69</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $1.28 - $4.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $6.72 - $8.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $8.96 - $10.75</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Plaquenil Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $0.18</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867145"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Plaquenil: 200 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg</p></div>
<div class="block adm drugH1Div" id="F180838"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer with food or milk. Do not crush or divide film-coated tablets per the manufacturer; the tablets have a bitter taste (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1942444']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1942444'])">Ref</a></span>). In patients unable to swallow tablets, it has been recommended that tablets may be crushed and mixed with a small amount of applesauce, chocolate syrup, or jelly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1'])">Ref</a></span>), or an extemporaneous suspension may be compounded (See Extemporaneously Prepared).</p></div>
<div class="block admp drugH1Div" id="F52617879"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with food or milk. Do not crush or divide film-coated tablets per the manufacturer; the tablets have a bitter taste (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1942444']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1942444'])">Ref</a></span>). In patients unable to swallow tablets, it has been recommended that tablets may be crushed and mixed with a small amount of applesauce, chocolate syrup, or jelly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1'])">Ref</a></span>), or an extemporaneous suspension may be compounded (See Extemporaneous Preparations).</p></div>
<div class="block use drugH1Div" id="F180837"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Lupus erythematosus:</b> Treatment of chronic discoid erythematosus and systemic lupus erythematosus in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Malaria:</b> Treatment of uncomplicated malaria caused by susceptible strains of <i>Plasmodium vivax</i>, <i>Plasmodium malariae</i>, <i>Plasmodium ovale</i>, and <i>Plasmodium falciparum</i>; prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. <b>Note:</b> The CDC guidelines also recommend hydroxychloroquine for chloroquine-sensitive <i>Plasmodium knowlesi</i> malaria (CDC 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Hydroxychloroquine is not effective against chloroquine- or hydroxychloroquine-resistant malaria strains of <i>Plasmodium</i> species; not recommended for treatment of complicated malaria, malaria prophylaxis in regions with chloroquine resistance, or treatment when the <i>Plasmodium</i> species has not been identified; hydroxychloroquine alone does not prevent relapses of <i>P. vivax</i> and <i>P. ovale</i> infections because it is not effective against the hypnozoite liver stage forms of these parasites.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatoid arthritis:</b> Treatment of acute and chronic rheumatoid arthritis in adults.</p></div>
<div class="block off-label drugH1Div" id="F25576480"><span class="drugH1">Use: Off-Label: Adult</span><p>Dermatomyositis, cutaneous disease; Porphyria cutanea tarda; Primary Sjögren disease (extraglandular manifestations); Q fever (Coxiella burnetii); Sarcoidosis, arthropathy; Sarcoidosis, cutaneous disease, extensive</p></div>
<div class="block mst drugH1Div" id="F180902"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Hydroxychloroquine may be confused with hydroCHLOROthiazide, hydrocortisone, hydroxyurea</p>
<p style="text-indent:-2em;margin-left:4em;">Plaquenil may be confused with Platinol</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299491"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C8 (minor), CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F180831"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agalsidase Alfa: Hydroxychloroquine may diminish the therapeutic effect of Agalsidase Alfa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agalsidase Beta: Hydroxychloroquine may diminish the therapeutic effect of Agalsidase Beta. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Artemether and Lumefantrine.  Management: Artemether/lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option. If combined, monitor patients for increased toxicities of both agents, including QTc interval prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azithromycin (Systemic): May enhance the cardiotoxic effect of Hydroxychloroquine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproMAZINE: Antimalarial Agents may increase the serum concentration of ChlorproMAZINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Hydroxychloroquine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ciprofloxacin (Systemic): Hydroxychloroquine may enhance the hyperglycemic effect of Ciprofloxacin (Systemic). Hydroxychloroquine may enhance the hypoglycemic effect of Ciprofloxacin (Systemic). Hydroxychloroquine may enhance the QTc-prolonging effect of Ciprofloxacin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: May enhance the hypoglycemic effect of Hydroxychloroquine. Hydroxychloroquine may enhance the QTc-prolonging effect of Citalopram.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Hydroxychloroquine may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Consider avoidance of this combination when possible. If combined, closely monitor for signs/symptoms of hemolytic reactions. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Hydroxychloroquine may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Escitalopram: May enhance the hypoglycemic effect of Hydroxychloroquine. Hydroxychloroquine may enhance the QTc-prolonging effect of Escitalopram.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemifloxacin: Hydroxychloroquine may enhance the hyperglycemic effect of Gemifloxacin. Hydroxychloroquine may enhance the hypoglycemic effect of Gemifloxacin. Hydroxychloroquine may enhance the QTc-prolonging effect of Gemifloxacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Glucose Lowering Effects: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levofloxacin-Containing Products (Systemic): Hydroxychloroquine may enhance the hyperglycemic effect of Levofloxacin-Containing Products (Systemic). Hydroxychloroquine may enhance the hypoglycemic effect of Levofloxacin-Containing Products (Systemic). Hydroxychloroquine may enhance the QTc-prolonging effect of Levofloxacin-Containing Products (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Levoketoconazole.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: Aminoquinolines (Antimalarial) may enhance the adverse/toxic effect of Mefloquine. Specifically, the risk for QTc-prolongation and the risk for convulsions may be increased.  Management: Avoid concurrent use, and delay administration of mefloquine until at least 12 hours after the last dose of an aminoquinoline antimalarial.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoprolol: Hydroxychloroquine may increase the serum concentration of Metoprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Moxifloxacin (Systemic): Hydroxychloroquine may enhance the hyperglycemic effect of Moxifloxacin (Systemic). Hydroxychloroquine may enhance the hypoglycemic effect of Moxifloxacin (Systemic). Hydroxychloroquine may enhance the QTc-prolonging effect of Moxifloxacin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Aminoquinolines (Antimalarial) may diminish the therapeutic effect of Rabies Vaccine.  Management: If coadministration is unavoidable during rabies post-exposure vaccination, give a 5th dose of the rabies vaccine. If coadministration is unavoidable during rabies pre-exposure vaccination, ensure antibody titers are greater than or equal to 0.5 IU/mL.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Remdesivir: Hydroxychloroquine may diminish the therapeutic effect of Remdesivir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May diminish the therapeutic effect of Hydroxychloroquine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparfloxacin: Hydroxychloroquine may enhance the hyperglycemic effect of Sparfloxacin. Hydroxychloroquine may enhance the hypoglycemic effect of Sparfloxacin. Hydroxychloroquine may enhance the QTc-prolonging effect of Sparfloxacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamoxifen: May enhance the adverse/toxic effect of Hydroxychloroquine. Specifically, concomitant use of tamoxifen and hydroxychloroquine may increase the risk of retinal toxicity.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54285062"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Hydroxychloroquine is recommended for use in patients with rheumatic and musculoskeletal diseases who are planning to become pregnant. Conception should be planned during a period of quiescent/low disease activity (ACR [Sammaritano 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Information related to paternal use of hydroxychloroquine is limited; however, available data have not shown hydroxychloroquine adversely impacts male fertility or increases the risk of adverse pregnancy outcomes when used prior to conception (Bermas 2019; Mouyis 2019). Hydroxychloroquine is recommended for use in patients with rheumatic and musculoskeletal diseases who are planning to father a child (ACR [Sammaritano 2020]).</p></div>
<div class="block pri drugH1Div" id="F5265901"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Hydroxychloroquine can be detected in the cord blood at delivery in concentrations similar to those in the maternal serum (Costedoat-Chalumeau 2002).</p>
<p style="text-indent:0em;margin-top:2em;">Adverse perinatal outcomes have not been associated with daily maternal doses of hydroxychloroquine ≤400 mg (Bérard 2021; Birru Talabi 2020; Costedoat-Chalumeau 2003; Diav-Citrin 2013; Huybrechts 2020). Retinal toxicity is a known risk following long-term use or high doses of hydroxychloroquine. Although animal reproduction studies have shown accumulation of chloroquine in fetal ocular tissues, an association between hydroxychloroquine and fetal ocular toxicity has not been confirmed in available human studies (Gaffar 2019; Levy 2001; Motta 2005; Osadchy 2011).</p>
<p style="text-indent:0em;margin-top:2em;">Maternal lupus is associated with adverse maternal and fetal events. If pregnancy is detected during therapy, hydroxychloroquine should not be stopped; cessation of hydroxychloroquine could precipitate a flare in maternal disease. Continued treatment is needed to control maternal disease and decrease the risk of maternal thrombosis and congenital heart block (Baer 2011; Izmirly 2012; Levy 2001; Petri 2020a; Tunks 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Available guidelines recommend treatment with hydroxychloroquine for systemic lupus erythematosus (SLE) during pregnancy. Hydroxychloroquine may be beneficial for some pregnant patients with antiphospholipid syndrome (ACR [Sammaritano 2020]; EULAR [Andreoli 2017]).</p>
<p style="text-indent:0em;margin-top:2em;">Malaria infection in pregnant patients may be more severe than in nonpregnant patients and has a high risk of maternal and perinatal morbidity and mortality. Therefore, pregnant patients and patients who are likely to become pregnant are advised to avoid travel to malaria-risk areas. When travel is unavoidable, pregnant patients should take precautions to avoid mosquito bites and use effective prophylactic medications. Hydroxychloroquine is recommended for the treatment of uncomplicated malaria during pregnancy in chloroquine-sensitive regions (refer to current guidelines) (CDC 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of hydroxychloroquine may be altered during pregnancy; however, dosage adjustments are not needed (Balevic 2019b). In one study, hydroxychloroquine concentrations ≤100 ng/mL correlated with increased disease activity and adverse maternal/fetal outcomes in patients with SLE, but there was no association between disease activity, pregnancy outcomes, and hydroxychloroquine blood levels in pregnant patients under treatment for LN (Balevic 2019a). Due to tissue binding, if hydroxychloroquine is discontinued, it would take 6 to 8 weeks to be completely eliminated.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to hydroxychloroquine is ongoing. Patients exposed to hydroxychloroquine while pregnant are encouraged to enroll in the pregnancy registry (1-877-311-8972).</p></div>
<div class="block brc drugH1Div" id="F20802474"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;">Hydroxychloroquine and the desethylchloroquine metabolite are present in breast milk (Cissoko 2010; Costedoat-Chalumeau 2002; Nation 1984; Ostensen 1985; Peng 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Breast milk concentrations of hydroxychloroquine were evaluated in 33 women. All women were treated with hydroxychloroquine for at least 1 year for various connective tissue diseases and were 1 to 16 weeks' postpartum. Maternal doses ranged from 200 mg every other day to 200 mg twice daily. Sampling occurred over a 12-hour dosing period. The average relative infant dose (RID) of hydroxychloroquine was calculated by the authors of the study to be 1.9% to 3.2% of the weight-adjusted maternal dose. The highest RID (9.8%) was observed in one woman taking hydroxychloroquine 200 mg twice daily (Peng 2019).</p>
<p style="text-indent:0em;margin-top:2em;">In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:0em;margin-top:2em;">Infants exposed to hydroxychloroquine via breast milk following chronic maternal administration, including one infant who was exposed for 30 months (Cimaz 2004), have been monitored for adverse effects; no negative impact on vision, growth, development, or otherwise has been noted (Cimaz 2004; Motta 2002; Motta 2005; Peng 2019; Tincani 2001).</p>
<p style="text-indent:0em;margin-top:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Hydroxychloroquine is considered to be compatible for use in breastfeeding mothers with rheumatic and musculoskeletal diseases (ACR [Sammaritano 2020]). Clinicians should note that when hydroxychloroquine is administered to breastfeeding patients for malaria, insufficient amounts are transferred via breast milk to provide chemoprophylaxis to the infant (CDC Yellow Book 2020).</p></div>
<div class="block mop drugH1Div" id="F180834"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Determinants for laboratory testing (ie, specific tests to monitor and frequency) should take into consideration patient's clinical status and duration of therapy (short-term versus long-term).</p>
<p style="text-indent:-2em;margin-left:2em;">CBC (with differential), liver function, and renal function at baseline and periodically during therapy; blood glucose (if symptoms of hypoglycemia occur); muscle strength (especially proximal, as a symptom of neuromyopathy) during long-term therapy; in patients at elevated risk of QTc prolongation, monitor ECG and serum electrolytes at baseline and as clinically indicated and correct any electrolyte imbalances to mitigate the risk of developing torsades de pointes; certain findings may require not initiating or discontinuing therapy. Serum concentration monitoring is recommended in the treatment of Q fever (CDC [Anderson 2013]).</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmologic exam at baseline (fundus examination within the first year plus visual fields and spectral-domain optical coherence tomography if maculopathy is present) to screen for retinal toxicity, followed by annual screening beginning after 5 years of use (or sooner if major risk factors are present) (Marmor [AAO 2016]). If ocular toxicity is suspected, monitor closely (retinal changes and visual disturbances may progress after drug discontinuation). Additionally, the manufacturer recommends an ocular exam include best corrected distance visual acuity and an automated threshold visual field of the central 10 degrees (24 degrees in patients of Asian ancestry as retinal toxicity may appear outside of the macula). Consider annual exams (without deferring 5 years) in patients with significant risk factors (eg, renal disease).</p></div>
<div class="block rer drugH1Div" id="F48902934"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Data suggest that individual blood concentrations do not correlate closely with dosage, weight, or clinical effectiveness. However, blood levels may be useful in patients with renal disease or as an aid in assessing compliance (Melles 2014). One study suggested a correlation of blood concentrations with ocular toxicity (ie, highest tertile of 1,177 to 3,503 ng/mL) and suggested dosage reduction in these patients (Petri 2020b); however, routine testing is not recommended by some experts (Wallace 2020). For the treatment of Q fever, a target range of 0.8 to 1.2 mg/L is recommended (CDC [Anderson 2013]; Petri 2020b).</p></div>
<div class="block pha drugH1Div" id="F180825"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">
<i>Antimalarial:</i> Interferes with digestive vacuole function within sensitive malarial parasites by increasing the pH and interfering with lysosomal degradation of hemoglobin; inhibits locomotion of neutrophils and chemotaxis of eosinophils; impairs complement-dependent antigen-antibody reactions.</p></div>
<div class="block phk drugH1Div" id="F180841"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Rheumatic disease: May require several weeks to respond </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Incomplete and variable (~70% [range: 25 to 100%]) (Tett 1993) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~40%, primarily albumin (Tett 1993)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic; metabolites include bidesethylchloroquine, desethylhydroxychloroquine, and desethylchloroquine (McChesney 1966)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: ~40 days (Tett 1993)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (15% to 25% [Tett 1993]; as metabolites and unchanged drug [up to 60%, McChesney 1966]); may be enhanced by urinary acidification</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F180846"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Plaquenil</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Axokine | Evoquin | Metirel | Narbon | Plaquenil</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo hydroxychloroquine | Apotex hydroxychloroquine | Hequinel | Hydroxychloroquine actavis | Hydroxychloroquine an | Hydroxychloroquine gh | Hydroxychloroquine rbx | Plaquenil | Terry white chemists hydroxychloroquine</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Corofree | Kovicin | Quinivir | Reumaflex | Roxiquin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Plaquenil</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Immard</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Morivid</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Papilup | Plaquinol | Reuquinol | Sulfato de hidroxicloroquina</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Hydroxychloroquine Zentiva | Plaquenil</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Drolsan | Hidroxicloroquina | Ilinol | Parenquil | Plaquinol | Quinilen | Reumazine</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Fen le | Hydroxychloroquine | Plaquenil</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Artroquin | Dimard | Dolquine | Hcqs | Hidroxicloroquina | Malarquin | Plaquinol</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Plaquenil</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Hydroxychloroquin aristo | Hydroxychloroquin axcount | Hydroxychloroquin heumann | Hydroxychloroquinsulfat Dr. Eberth | Plaquenil | Quensyl</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Corcirex | Hidroxicloroquina mamey | Plaquinol</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Concidor | Corcirex | Dimard | Etiquina | Hidroxicloroquina | Hidroxicloroquina bkf | Plaquinol</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Hydroxychloroquine | Oxiklorin | Plaquenil</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Futarhomal | Hydroquine | Plaquenil</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Dolquine | Duplaxil | Hidroxicloroquina aldo union | Hidroxicloroquina ratiopharm | Xanban</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ercoquin | Oxiklorin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Plaquenil</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Hydroxychloroquine sulphate | Plaquenil | Quinoric</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Plaquenil | Plaquenil s</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo hydroxyquine | Hcq | Plaquenil</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Plaquenil</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Farneltik | Sanloquin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Plaquenil</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Plaquenil</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Axemal | Cartiquin | Coviq | Hcqs | Hetq | Hetquenil | Hiquine s | Hq fine | Hqtor | Hydire | Hydrocad | Hydroquin | Hydrowin | Imulast | Mcqs | Orthokind | Oxcq | Oxy q | Qdmrd | Ra quin | Rhq | Rutor | Vohq | Winflam | Zy q</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Plaquneer</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Idrossiclorochina Doc | Plaquenil</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Advaquenil | Plaquenil</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Ercoquin | Plaquenil</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Hcqs | Oxcq</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Acyquin | Aruquin | Chloqueen | Duroc | Erquin | Folanil | Haloxin | Halrochrosin | Hydroquine | Hyrokin | Oxiklorin | Oxyquine | Rumaquine | Yuma</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Plaquenil</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Corvaquine | Dolquine | Plaquenil</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Plaquenil</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Plaquenil</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Plaquenil</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Advaquenil</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Himanix | Plaquenil</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Hcqs | Plaquenil | Uniquin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Hydroxychloroquine | Hydroxychloroquinesulfaat focus | Plaquenil</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ercoquin | Hydroxychloroquin | Plaquenil | Quinoric</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Plaquenil</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Coronil | Droloquin | Hcqs | Hidroxicloroquina sulfato | Hidroxiplus | Plaquinol | Reumaquin</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Hcqs | Plaquenil | Stalhyquin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Alaska | Hcq | Hs 200 | Mcquine | Oxyclor | Plaquin h | Rheuquin | Roxyquin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Duplaxil | Idrossiclorochina Doc | Plaquenil | Quensyl | Zy q</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Hydroxychloroquine | Plaquenil | Quineprox</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Hidroxicloroquina | Plaquinol</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Hidroxicloroquina bioteng | Hidroxicloroquina dasanti | Hidroxicloroquina empa | Hidroxicloroquina heisecke | Hidroxicloroquina prosalud | Plaquinol | Supretic | Supretic forte</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Advaquenil | Plaquenil</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Hydroxychloroquine | Immard | Plaquenil</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo hydroxychloroquine | Apo hydroxyquine | Arthosave | Plaquenil</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Plaquenil</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Haloxin | Plaquenil</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Hyplaxy | Quinoric</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Plaquenil</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Hcqs | Hquine | Hydroquin | Plaquenil | Plaquenil sulfate | Quinnel | Zyquenil</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Plaquenil</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Korokin | Plaquinol</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Be easy | Belian | Chloguin | Geniquin | Hydroquine | Lisen | Plaquenil | Plaquil</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Immard | Plaquenil | Xinoxis</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Evoquin | Hcqs | Metirel | Plaquinol</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Plaquinol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-18720511">
<a name="18720511"></a>Abdel-Hamid H, Oddis CV, Lacomis D. Severe hydroxychloroquine myopathy. <i>Muscle Nerve</i>. 2008;38(3):1206‐1210. doi:10.1002/mus.21091<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/18720511/pubmed" id="18720511" target="_blank">18720511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32626630">
<a name="32626630"></a>Abdelmaseih R, Abdelmasih R, Hasan M, Tadepalli S, Patel J. Serious adverse events associated with hydroxychloroquine amidst COVID-19 pandemic: case series and literature review. <i>Cureus</i>. 2020;12(6):e8415. doi:10.7759/cureus.8415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/32626630/pubmed" id="32626630" target="_blank">32626630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28099213">
<a name="28099213"></a>Abou Assalie N, Durcan R, Durcan L, Petri MA. Hydroxychloroquine-induced erythema multiforme. <i>J Clin Rheumatol</i>. 2017;23(2):127-128. doi:10.1097/RHU.0000000000000417<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/28099213/pubmed" id="28099213" target="_blank">28099213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30187668">
<a name="30187668"></a>Agarwal V, Agrawal V, Aggarwal A, et al; Arthritis in Sarcoidosis Group (ASG). Arthritis in sarcoidosis: a multicentric study from India. <i>Int J Rheum Dis</i>. 2018;21(9):1728-1733. doi:10.1111/1756-185X.13349<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/30187668/pubmed" id="30187668" target="_blank">30187668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sequeira.2019">
<a name="Sequeira.2019"></a>Aggarwal R. Sarcoid arthropathy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 25, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23535757">
<a name="23535757"></a>Anderson A, Bijlmer H, Fournier PE, et al. Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group. <i>MMWR Recomm Rep</i>. 2013;62(RR-03):1-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/23535757/pubmed" id="23535757" target="_blank">23535757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27457513">
<a name="27457513"></a>Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. <i>Ann Rheum Dis</i>. 2017;76(3):476-485. doi:10.1136/annrheumdis-2016-209770<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/27457513/pubmed" id="27457513" target="_blank">27457513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16027300">
<a name="16027300"></a>Ang GC, Werth VP. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. <i>Arch Dermatol</i>. 2005;141(7):855-859. doi: 10.1001/archderm.141.7.855<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/16027300/pubmed" id="16027300" target="_blank">16027300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32702948">
<a name="32702948"></a>Arıkan F, Yıldız Y, Ercan T, et al. Hydroxychloroquine-associated thrombotic thrombocytopenic purpura. <i>Turk J Haematol</i>. 2020;37(4):302-304. doi:10.4274/tjh.galenos.2020.2020.0322<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/32702948/pubmed" id="32702948" target="_blank">32702948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7704464">
<a name="7704464"></a>Avina-Zubieta JA, Johnson ES, Suarez-Almazor ME, Russell AS. Incidence of myopathy in patients treated with antimalarials. A report of three cases and a review of the literature. <i>Br J Rheumatol</i>. 1995;34(2):166‐170. doi:10.1093/rheumatology/34.2.166<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/7704464/pubmed" id="7704464" target="_blank">7704464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23154245">
<a name="23154245"></a>Bae SM, Jung HO, Ihm SM, et al. Hydroxychloroquine-induced cardiomyopathy that presented as pulmonary hypertension: a newly noted complication. <i>Cardiology</i>. 2012;123(3):197-200. doi:10.1159/000343142<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/23154245/pubmed" id="23154245" target="_blank">23154245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baer.1">
<a name="Baer.1"></a>Baer AN, Vivino FB. Treatment of Sjögren's syndrome: Constitutional and non-sicca organ-based manifestations. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 15, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22112525">
<a name="22112525"></a>Baer AN, Witter FR, Petri M. Lupus and Pregnancy. <i>Obstet Gynecol Surv</i>. 2011;66(10):639-653.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/22112525/pubmed" id="22112525" target="_blank">22112525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28355984">
<a name="28355984"></a>Bahloul E, Jallouli M, Garbaa S, et al. Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases. <i>Lupus</i>. 2017;26(12):1304‐1308. doi:10.1177/0961203317700486<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/28355984/pubmed" id="28355984" target="_blank">28355984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24138979">
<a name="24138979"></a>Bailey K, McKee D, Wismer J, Shear N. Acute generalized exanthematous pustulosis induced by hydroxychloroquine: first case report in Canada and review of the literature. <i>J Cutan Med Surg</i>. 2013;17(6):414‐418. doi:10.2310/7750.2013.12105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/24138979/pubmed" id="24138979" target="_blank">24138979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30275257">
<a name="30275257"></a>Balevic SJ, Cohen-Wolkowiez M, Eudy AM, Green TP, Schanberg LE, Clowse MEB. Hydroxychloroquine levels throughout pregnancies complicated by rheumatic disease: implications for maternal and neonatal outcomes. <i>J Rheumatol</i>. 2019a;46(1):57-63. doi:10.3899/jrheum.180158<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/30275257/pubmed" id="30275257" target="_blank">30275257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30255310">
<a name="30255310"></a>Balevic SJ, Green TP, Clowse MEB, Eudy AM, Schanberg LE, Cohen-Wolkowiez M. Pharmacokinetics of hydroxychloroquine in pregnancies with rheumatic diseases. <i>Clin Pharmacokinet</i>. 2019b;58(4):525-533. doi:10.1007/s40262-018-0712-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/30255310/pubmed" id="30255310" target="_blank">30255310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32259313">
<a name="32259313"></a>Barlow A, Landolf KM, Barlow B, et al. Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019 [published online April 7, 2020]. <i>Pharmacotherapy</i>. doi:10.1002/phar.2398<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/32259313/pubmed" id="32259313" target="_blank">32259313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34140301">
<a name="34140301"></a>Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. <i>Eur Respir J.</i> 2021;58(6):2004079. doi:10.1183/13993003.04079-2020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/34140301/pubmed" id="34140301" target="_blank">34140301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. <i>Drug Saf</i>. 2019;42(8):973‐992. doi:10.1007/s40264-019-00825-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34408654">
<a name="34408654"></a>Bérard A, Sheehy O, Zhao JP, Vinet E, Quach C, Bernatsky S. Chloroquine and hydroxychloroquine use during pregnancy and the risk of adverse pregnancy outcomes using real-world evidence. <i>Front Pharmacol</i>. 2021;12:722511. doi:10.3389/fphar.2021.722511<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/34408654/pubmed" id="34408654" target="_blank">34408654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851469">
<a name="22851469"></a>Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) Recommendations For the Management of Adult and Paediatric Lupus Nephritis. <i>Ann Rheum Dis</i>. 2012;71(11):1771-1782.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/22851469/pubmed" id="22851469" target="_blank">22851469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32205567">
<a name="32205567"></a>Birru Talabi M, Clowse MEB. Antirheumatic medications in pregnancy and breastfeeding.<i> Curr Opin Rheumatol</i>. 2020;32(3):238-246. doi:10.1097/BOR.0000000000000710<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/32205567/pubmed" id="32205567" target="_blank">32205567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183‐198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30223310">
<a name="30223310"></a>Borik L, Petzelbauer P, Quint T, Wöhrl S, Kinaciyan T, Heil PM. Type IV allergy to antimalarials can mimic cutaneous manifestations of lupus erythematosus. <i>J Eur Acad Dermatol Venereol</i>. 2019;33(3):e94‐e96. doi:10.1111/jdv.15249<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/30223310/pubmed" id="30223310" target="_blank">30223310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94‐105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7939166">
<a name="7939166"></a>Bustos MD, Gay F, Diquet B, Thomare P, Warot D. The pharmacokinetics and electrocardiographic effects of chloroquine in healthy subjects. <i>Trop Med Parasitol</i>. 1994;45(2):83‐86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/7939166/pubmed" id="7939166" target="_blank">7939166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18222983">
<a name="18222983"></a>Cansu DU, Korkmaz C. Hypoglycaemia induced by hydroxychloroquine in a non-diabetic patient treated for RA.<i> Rheumatology (Oxford)</i>. 2008;47(3):378-379.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/18222983/pubmed" id="18222983" target="_blank">18222983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18177777">
<a name="18177777"></a>Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. <i>Lancet</i>. 2008;371(9606):64-74. doi:10.1016/S0140-6736(08)60073-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/18177777/pubmed" id="18177777" target="_blank">18177777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21965696">
<a name="21965696"></a>Caramaschi P, Barbazza R, Tinazzi I, Biasi D. Desensitization to hydroxychloroquine: 4 cases. <i>J Rheumatol</i>. 2011;38(10):2267. doi:10.3899/jrheum.110345<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/21965696/pubmed" id="21965696" target="_blank">21965696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27390247">
<a name="27390247"></a>Carsons SE, Vivino FB, Parke A, et al. Treatment guidelines for rheumatologic manifestations of Sjögren's syndrome: use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain. <i>Arthritis Care Res (Hoboken)</i>. 2017;69(4):517-527. doi: 10.1002/acr.22968<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/27390247/pubmed" id="27390247" target="_blank">27390247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16096334">
<a name="16096334"></a>Casado E, Gratacós J, Tolosa C, et al. Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. <i>Ann Rheum Dis</i>. 2006;65(3):385‐390. doi:10.1136/ard.2004.023200<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/16096334/pubmed" id="16096334" target="_blank">16096334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). <i>CDC Yellow Book 2020: Health Information for International Travel</i>. Oxford University Press; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2">
<a name="CDC.2"></a>Centers for Disease Control and Prevention (CDC). Treatment of malaria: guidelines for clinicians (United States). <a href="https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html" target="_blank">https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html</a>. Updated May 29, 2020. Accessed June 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26729969">
<a name="26729969"></a>Charfi O, Kastalli S, Sahnoun R, Lakhoua G. Hydroxychloroquine-induced acute generalized exanthematous pustulosis with positive patch-testing. <i>Indian J Pharmacol</i>. 2015;47(6):693‐694. doi:10.4103/0253-7613.169589<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/26729969/pubmed" id="26729969" target="_blank">26729969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29858838">
<a name="29858838"></a>Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. <i>Drug Saf</i>. 2018;41(10):919‐931. doi:10.1007/s40264-018-0689-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/29858838/pubmed" id="29858838" target="_blank">29858838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16615675">
<a name="16615675"></a>Chen CY, Wang FL, Lin CC. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. <i>Clin Toxicol (Phila)</i>. 2006;44(2):173‐175. doi:10.1080/15563650500514558<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/16615675/pubmed" id="16615675" target="_blank">16615675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37484756">
<a name="37484756"></a>Chen J, Falcone LM, Karunamurthy AD, Ho J, English JC 3rd. Hydroxychloroquine-induced repetitive atypical pustular drug eruptions in the same patient separated by 12 years. <i>Clin Case Rep</i>. 2023;11(7):e7677. Pdoi:10.1002/ccr3.7677<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/37484756/pubmed" id="37484756" target="_blank">37484756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15725234">
<a name="15725234"></a>Chong WS, Tan HH, Tan SH. Cutaneous sarcoidosis in Asians: a report of 25 patients from Singapore. <i>Clin Exp Dermatol</i>. 2005;30(2):120-124. doi:10.1111/j.1365-2230.2005.01729.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/15725234/pubmed" id="15725234" target="_blank">15725234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15457485">
<a name="15457485"></a>Cimaz R, Brucato A, Meregalli E, Muscará M, Sergi P. Electroretinograms of children born to mothers treated with hydroxychloroquine during pregnancy and breast-feeding: comment on the article by Costedoat-Chalumeau et al. <i>Arthritis Rheum</i>. 2004;50(9):3056-3057; author reply 3057-3058.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/15457485/pubmed" id="15457485" target="_blank">15457485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cissoko.1">
<a name="Cissoko.1"></a>Cissoko HRJ, Zahr N, Darrouzain F, Jonville-Bera AP, Autret-Leca E. Breast milk concentrations of hydroxychloroquine. <i>Fundam Clin Pharmacol. </i>2010;24(suppl 1):420. Abstract 420-106. doi.org/10.1111/j.1472-8206.2010.00819.x</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Clarke.1">
<a name="Clarke.1"></a>Clarke J. Initial management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 5, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7492125">
<a name="7492125"></a>Cosnes A, Amaudric F, Gherardi R, et al. Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids. <i>Arch Dermatol</i>. 1995;131(12):1381-1385. doi: 10.1001/archderm.131.12.1381<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/7492125/pubmed" id="7492125" target="_blank">7492125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11953993">
<a name="11953993"></a>Costedoat-Chalumeau N, Amoura Z, Aymard G, et al. Evidence of Transplacental Passage of Hydroxychloroquine in Humans.<i> Arthritis Rheum</i>. 2002;46(4):1123-1124.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/11953993/pubmed" id="11953993" target="_blank">11953993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14613284">
<a name="14613284"></a>Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. <i>Arthritis Rheum</i>. 2003;48(11):3207-3211. doi:10.1002/art.11304<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/14613284/pubmed" id="14613284" target="_blank">14613284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17202178">
<a name="17202178"></a>Costedoat-Chalumeau N, Hulot JS, Amoura Z, et al. Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. <i>Rheumatology (Oxford)</i>. 2007;46(5):808-810. doi:10.1093/rheumatology/kel402<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/17202178/pubmed" id="17202178" target="_blank">17202178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Costedoat.1">
<a name="Costedoat.1"></a>Costedoat-Chalumeau N, Isenberg D, Petri M. Letter in response to the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis <i>et al</i>. <i>Ann Rheum Dis</i>. 2019;0:1.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24268495">
<a name="24268495"></a>Das P, Rai A, Chopra A, Philbrick K. Psychosis likely induced by hydroxychloroquine in a patient with chronic Q fever: a case report and clinically relevant review of pharmacology. <i>Psychosomatics</i>. 2014;55(4):409‐413. doi:10.1016/j.psym.2013.06.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/24268495/pubmed" id="24268495" target="_blank">24268495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28913747">
<a name="28913747"></a>Demarchi J, Papasidero S, Medina MA, et al. Primary Sjögren's syndrome: extraglandular manifestations and hydroxychloroquine therapy. <i>Clin Rheumatol</i>. 2017;36(11):2455-2460. doi:10.1007/s10067-017-3822-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/28913747/pubmed" id="28913747" target="_blank">28913747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23602891">
<a name="23602891"></a>Diav-Citrin O, Blyakhman S, Shechtman S, Ornoy A. Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study. <i>Reprod Toxicol</i>. 2013;39:58-62. doi:10.1016/j.reprotox.2013.04.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/23602891/pubmed" id="23602891" target="_blank">23602891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16738856">
<a name="16738856"></a>Dosso A, Rungger-Brändle E. <i>In vivo</i> confocal microscopy in hydroxychloroquine-induced keratopathy. <i>Graefes Arch Clin Exp Ophthalmol</i>. 2007; 245(2):318-320.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/16738856/pubmed" id="16738856" target="_blank">16738856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8246830">
<a name="8246830"></a>Drugs for Parasitic Infections. <i>Med Lett Drugs Ther</i>. 1993;35(911):111-122.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/8246830/pubmed" id="8246830" target="_blank">8246830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29186260">
<a name="29186260"></a>Duman H, Topal IO, Kocaturk E, Cure K, Mansuroglu I. Acute generalized exanthematous pustulosis induced by hydroxychloroquine: a case with atypical clinical presentation. <i>An Bras Dermatol</i>. 2017;92(3):404‐406. doi:10.1590/abd1806-4841.20175561<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/29186260/pubmed" id="29186260" target="_blank">29186260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29787487">
<a name="29787487"></a>Eldeeb M, Chan EW, Omar A. Case report: hydroxychloroquine retinopathy. <i>Optom Vis Sci</i>. 2018;95(6):545-549. doi:10.1097/OPX.0000000000001226<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/29787487/pubmed" id="29787487" target="_blank">29787487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3763254">
<a name="3763254"></a>Emery H. Clinical Aspects of Systemic Lupus Erythematosus in Childhood. <i>Pediatr Clin North Am</i>. 1986;33(5):1177-1190.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/3763254/pubmed" id="3763254" target="_blank">3763254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3826099">
<a name="3826099"></a>Estes ML, Ewing-Wilson D, Chou SM, et al. Chloroquine neuromyotoxicity. Clinical and pathologic perspective. <i>Am J Med</i>. 1987;82(3):447‐455. doi:10.1016/0002-9343(87)90444-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/3826099/pubmed" id="3826099" target="_blank">3826099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31201171">
<a name="31201171"></a>Fanouriakis A, Bertsias G, Boumpas DT. Hydroxychloroquine dosing in systemic lupus erythematosus: response to 'Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis <i>et al'</i> by Costedoat-Chalumeau <i>et al</i>. <i>Ann Rheum Dis</i>. 2020;79(8):e91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/31201171/pubmed" id="31201171" target="_blank">31201171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30926722">
<a name="30926722"></a>Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Ann Rheum Dis</i>. 2019;78(6):736-745.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/30926722/pubmed" id="30926722" target="_blank">30926722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29924251">
<a name="29924251"></a>Fernandes MRN, Soares DBR, Thien CI, Carneiro S. Hydroxychloroquine ototoxicity in a patient with systemic lupus erythematosus. <i>An Bras Dermatol</i>. 2018;93(3):469-470. doi:10.1590/abd1806-4841.20187615<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/29924251/pubmed" id="29924251" target="_blank">29924251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32236844">
<a name="32236844"></a>Fiehn C, Ness T, Weseloh C, et al. Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review. <i>Z Rheumatol</i>. Published online March 31, 2020. doi:10.1007/s00393-020-00785-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/32236844/pubmed" id="32236844" target="_blank">32236844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32725108">
<a name="32725108"></a>Figliozzi S, Rizzo S, De Gaspari M, Tarantini G. End-stage heart failure secondary to low-dose hydroxychloroquine treatment. <i>Eur Heart J</i>. 2021;42(2):207. doi:10.1093/eurheartj/ehaa595<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/32725108/pubmed" id="32725108" target="_blank">32725108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8278823">
<a name="8278823"></a>Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. <i>Semin Arthritis Rheum</i>. 1993;23(2)(suppl 1):S82-S91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/8278823/pubmed" id="8278823" target="_blank">8278823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8803908">
<a name="8803908"></a>Fox RI, Dixon R, Guarrasi V, Krubel S. Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. <i>Lupus</i>. 1996;5(suppl 1):S31-S36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/8803908/pubmed" id="8803908" target="_blank">8803908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34101387">
<a name="34101387"></a>Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2021;73(7):924-939. doi:10.1002/acr.24596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/34101387/pubmed" id="34101387" target="_blank">34101387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30418703">
<a name="30418703"></a>Gaffar R, Pineau CA, Bernatsky S, Scott S, Vinet É. Risk of ocular anomalies in children exposed In utero to antimalarials: a systematic literature review. <i>Arthritis Care Res (Hoboken)</i>. 2019;71(12):1606-1610. doi:10.1002/acr.23808<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/30418703/pubmed" id="30418703" target="_blank">30418703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7567188">
<a name="7567188"></a>Giannini EH, Cawkwell GD. Drug Treatment in Children With Juvenile Rheumatoid Arthritis. Past, Present, and Future. <i>Pediatr Clin North Am</i>. 1995;42(5):1099-1125.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/7567188/pubmed" id="7567188" target="_blank">7567188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31085265">
<a name="31085265"></a>Gonzalez CD, Hansen C, Clarke JT. Adverse cutaneous drug reactions with antimalarials in cutaneous lupus and dermatomyositis: A retrospective cohort study. <i>J Am Acad Dermatol</i>. 2019;81(3):859‐860. doi:10.1016/j.jaad.2019.04.068<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/31085265/pubmed" id="31085265" target="_blank">31085265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25027140">
<a name="25027140"></a>Gottenberg JE, Ravaud P, Puéchal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. <i>JAMA</i>. 2014;312(3):249-258. doi:10.1001/jama.2014.7682<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/25027140/pubmed" id="25027140" target="_blank">25027140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22086858">
<a name="22086858"></a>Gould FK, Denning DW, Elliott TS, et al. Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy. <i>J Antimicrob Chemother</i>. 2012;67(2):269-289.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/22086858/pubmed" id="22086858" target="_blank">22086858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9135223">
<a name="9135223"></a>Grierson DJ. Hydroxychloroquine and visual screening in a rheumatology outpatient clinic. <i>Ann Rheum Dis</i>. 1997;56(3):188-190. doi:10.1136/ard.56.3.188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/9135223/pubmed" id="9135223" target="_blank">9135223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22556106">
<a name="22556106"></a>Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology Guidelines For Screening, Treatment, and Management of Lupus Nephritis. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(6):797-808.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/22556106/pubmed" id="22556106" target="_blank">22556106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32961123">
<a name="32961123"></a>Huybrechts KF, Bateman BT, Zhu Y, et al. Hydroxychloroquine early in pregnancy and risk of birth defects. <i>Am J Obstet Gynecol</i>. Published online September 19, 2020. doi:10.1016/j.ajog.2020.09.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/32961123/pubmed" id="32961123" target="_blank">32961123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Accord.1">
<a name="Accord.1"></a>Hydroxychloroquine tablet [prescribing information]. Durham, NC: Accord Healthcare Inc; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DrReddy.1">
<a name="DrReddy.1"></a>Hydroxychloroquine tablet [prescribing information]. Princeton, NJ: Dr. Reddy's Laboratories Inc; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22626746">
<a name="22626746"></a>Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal Use of Hydroxychloroquine Is Associated With a Reduced Risk of Recurrent Anti-SSA/Ro-Antibody-Associated Cardiac Manifestations of Neonatal Lupus. <i>Circulation</i>. 2012;126(1):76-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/22626746/pubmed" id="22626746" target="_blank">22626746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25989906">
<a name="25989906"></a>Jallouli M, Galicier L, Zahr N, et al; Plaquenil Lupus Systemic Study Group. Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. <i>Arthritis Rheumatol</i>. 2015;67(8):2176-2184. doi:10.1002/art.39194<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/25989906/pubmed" id="25989906" target="_blank">25989906</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22160434">
<a name="22160434"></a>Jallouli M, Saadoun D, Eymard B, et al. The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature. <i>J Neurol</i>. 2012;259(7):1290‐1297. doi:10.1007/s00415-011-6335-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/22160434/pubmed" id="22160434" target="_blank">22160434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4093940">
<a name="4093940"></a>James WD, Dawson N, Rodman OG. The treatment of dermatomyositis with hydroxychloroquine. <i>J Rheumatol</i>. 1985;12(6):1214-1216.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/4093940/pubmed" id="4093940" target="_blank">4093940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2212149">
<a name="2212149"></a>Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. <i>J Am Acad Dermatol</i>. 1990;23(3, pt 1):487-489. doi: 10.1016/0190-9622(90)70246-e<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/2212149/pubmed" id="2212149" target="_blank">2212149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10215761">
<a name="10215761"></a>Jones SK. Ocular Toxicity and Hydroxychloroquine: Guidelines for Screening. <i>Br J Derm</i>. 1999;140(1):3-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/10215761/pubmed" id="10215761" target="_blank">10215761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30401979">
<a name="30401979"></a>Jorge A, Ung C, Young LH, Melles RB, Choi HK. Hydroxychloroquine retinopathy - implications of research advances for rheumatology care. <i>Nat Rev Rheumatol</i>. 2018;14(12):693‐703. doi:10.1038/s41584-018-0111-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/30401979/pubmed" id="30401979" target="_blank">30401979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24062937">
<a name="24062937"></a>Joyce E, Fabre A, Mahon N. Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review. <i>Eur Heart J Acute Cardiovasc Care</i>. 2013;2(1):77‐83. doi:10.1177/2048872612471215<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/24062937/pubmed" id="24062937" target="_blank">24062937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28077146">
<a name="28077146"></a>Kim S, Kahn P, Robinson AB, et al. Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. <i>Pediatr Rheumatol Online J</i>. 2017;15(1):1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/28077146/pubmed" id="28077146" target="_blank">28077146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8323383">
<a name="8323383"></a>Kruize AA, Hené RJ, Kallenberg CG, et al. Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. <i>Ann Rheum Dis</i>. 1993;52(5):360-364. doi:10.1136/ard.52.5.360<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/8323383/pubmed" id="8323383" target="_blank">8323383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27859683">
<a name="27859683"></a>Kuhn A, Aberer E, Bata-Csörgő Z, et al. S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). <i>J Eur Acad Dermatol Venereol</i>. 2017;31(3):389-404. doi:10.1111/jdv.14053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/27859683/pubmed" id="27859683" target="_blank">27859683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23997576">
<a name="23997576"></a>Kumar P, Banik S. Pharmacotherapy options in rheumatoid arthritis. <i>Clin Med Insights Arthritis Musculoskelet Disord</i>. 2013;6:35-43. doi:10.4137/CMAMD.S5558<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/23997576/pubmed" id="23997576" target="_blank">23997576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27548593">
<a name="27548593"></a>Lam NC, Ghetu MV, Bieniek ML. Systemic lupus erythematosus: primary care approach to diagnosis and management. <i>Am Fam Physician</i>. 2016;94(4):284-294.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/27548593/pubmed" id="27548593" target="_blank">27548593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19727917">
<a name="19727917"></a>Lateef A, Tan KB, Lau TC. Acute generalized exanthematous pustulosis and toxic epidermal necrolysis induced by hydroxychloroquine. <i>Clin Rheumatol</i>. 2009;28(12):1449‐1452. doi:10.1007/s10067-009-1262-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/19727917/pubmed" id="19727917" target="_blank">19727917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11961185">
<a name="11961185"></a>Leckie MJ, Rees RG. Stevens-Johnson syndrome in association with hydroxychloroquine treatment for rheumatoid arthritis. <i>Rheumatology (Oxford)</i>. 2002;41(4):473‐474. doi:10.1093/rheumatology/41.4.473<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/11961185/pubmed" id="11961185" target="_blank">11961185</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11434574">
<a name="11434574"></a>Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in Lupus Pregnancy: Double-Blind and Placebo-Controlled Study. <i>Lupus</i>. 2001;10(6):401-404.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/11434574/pubmed" id="11434574" target="_blank">11434574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27040960">
<a name="27040960"></a>Luzzatto L, Nannelli C, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. <i>Hematol Oncol Clin North Am</i>. 2016;30(2):373-393. doi:10.1016/j.hoc.2015.11.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/27040960/pubmed" id="27040960" target="_blank">27040960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8175002">
<a name="8175002"></a>Makin AJ, Wendon J, Fitt S, Portmann BC, Williams R. Fulminant hepatic failure secondary to hydroxychloroquine. <i>Gut</i>. 1994;35(4):569-570. doi:10.1136/gut.35.4.569<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/8175002/pubmed" id="8175002" target="_blank">8175002</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28258476">
<a name="28258476"></a>Manzo C, Gareri P, Castagna A. Psychomotor agitation following treatment with hydroxychloroquine. <i>Drug Saf Case Rep</i>. 2017;4(1):6. doi:10.1007/s40800-017-0048-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/28258476/pubmed" id="28258476" target="_blank">28258476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20222881">
<a name="20222881"></a>Marks SD, Tullus K. Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis. <i>Acta Paediatr</i>. 2010;99(7):967-974.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/20222881/pubmed" id="20222881" target="_blank">20222881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26992838">
<a name="26992838"></a>Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF; American Academy of Ophthalmology (AAO). Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). <i>Ophthalmology</i>. 2016;123(6):1386-1394. doi: 10.1016/j.ophtha.2016.01.058<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/26992838/pubmed" id="26992838" target="_blank">26992838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29948492">
<a name="29948492"></a>Mascolo A, Berrino PM, Gareri P, et al. Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article. <i>Inflammopharmacology</i>. 2018;26(5):1141‐1149. doi:10.1007/s10787-018-0498-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/29948492/pubmed" id="29948492" target="_blank">29948492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16463436">
<a name="16463436"></a>Mates M, Zevin S, Breuer GS, Navon P, Nesher G. Desensitization to hydroxychloroquine--experience of 4 patients. <i>J Rheumatol</i>. 2006;33(4):814‐816.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/16463436/pubmed" id="16463436" target="_blank">16463436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16932698">
<a name="16932698"></a>Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjögren's syndrome. <i>Nat Clin Pract Rheumatol</i>. 2006;2(5):252-261. doi:10.1038/ncprheum0165<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/16932698/pubmed" id="16932698" target="_blank">16932698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4957157">
<a name="4957157"></a>McChesney EW, Conway WD, Banks WF, et al. Studies of the metabolism of some compounds of the 4-amino-7-chloroquinolone series. <i>J Pharmacol Exp Ther</i>. 1966;151(3):482-493.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/4957157/pubmed" id="4957157" target="_blank">4957157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1942444">
<a name="1942444"></a>McLaughlin GE. Coated plaquenil tablets: potential risk for children? <i>JAMA</i>. 1991;266(20):2832.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/1942444/pubmed" id="1942444" target="_blank">1942444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25275721">
<a name="25275721"></a>Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy [published correction appears in <i>JAMA Ophthalmol</i>. 2014;132(12):1493]. <i>JAMA Ophthalmol</i>. 2014;132(12):1453-1460.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/25275721/pubmed" id="25275721" target="_blank">25275721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23794723">
<a name="23794723"></a>Million M, Walter G, Thuny F, Habib G, Raoult D. Evolution from acute Q fever to endocarditis is associated with underlying valvulopathy and age and can be prevented by prolonged antibiotic treatment. <i>Clin Infect Dis</i>. 2013;57(6):836-844. doi:10.1093/cid/cit419<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/23794723/pubmed" id="23794723" target="_blank">23794723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18491485">
<a name="18491485"></a>Modi S, Rosen T. Micropapular cutaneous sarcoidosis: case series successfully managed with hydroxychloroquine sulfate. <i>Cutis</i>. 2008;81(4):351-354.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/18491485/pubmed" id="18491485" target="_blank">18491485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28556555">
<a name="28556555"></a>Mohammad S, Clowse MEB, Eudy AM, Criscione-Schreiber LG. Examination of hydroxychloroquine use and hemolytic anemia in G6PDH-deficient patients. <i>Arthritis Care Res (Hoboken)</i>. 2018;70(3):481‐485. doi:10.1002/acr.23296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/28556555/pubmed" id="28556555" target="_blank">28556555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11853823">
<a name="11853823"></a>Motta M, Tincani A, Faden D, Zinzini E, Chirico G. Antimalarial agents in pregnancy. <i>Lancet</i>. 2002;359(9305):524-525.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/11853823/pubmed" id="11853823" target="_blank">11853823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15496869">
<a name="15496869"></a>Motta M, Tincani A, Faden D, et al. Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. <i>J Perinatol</i>. 2005;25(2):86-89.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/15496869/pubmed" id="15496869" target="_blank">15496869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21406675">
<a name="21406675"></a>Muthukrishnan P, Roukoz H, Grafton G, Jessurun J, Colvin-Adams M. Hydroxychloroquine-induced cardiomyopathy: a case report. <i>Circ Heart Fail</i>. 2011;4(2):e7‐e8. doi:10.1161/CIRCHEARTFAILURE.110.959916<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/21406675/pubmed" id="21406675" target="_blank">21406675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-MGFA.1">
<a name="MGFA.1"></a>Myasthenia Gravis Foundation of America (MGFA). <i>Drugs and MG: Cautionary Drugs</i>. https://myasthenia.org/Portals/0/Cautionary_Drugs_2020_1.pdf. Accessed June 17, 2020</div>
</li>
<li>
<div class="reference">
                  Nation RL, Hackett LP, Dusci LJ, Ilett KF. Excretion of hydroxychloroquine in human milk. <i>Br J Clin Pharmacol</i>. 1984;17(3):368-369.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management. Clinical guideline [CG183]. September 3, 2014. https://www.nice.org.uk/guidance/cg183. Accessed May 26, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23755969">
<a name="23755969"></a>O'Dell JR, Mikuls TR, Taylor TH, et al; CSP 551 RACAT Investigators. Therapies for active rheumatoid arthritis after methotrexate failure. <i>N Engl J Med</i>. 2013;369(4):307-318. doi:10.1056/NEJMoa1303006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/23755969/pubmed" id="23755969" target="_blank">23755969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27478650">
<a name="27478650"></a>O'Laughlin JP, Mehta PH, Wong BC. Life threatening severe QTc prolongation in patient with systemic lupus erythematosus due to hydroxychloroquine. <i>Case Rep Cardiol</i>. 2016;2016:4626279. doi:10.1155/2016/4626279<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/27478650/pubmed" id="27478650" target="_blank">27478650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2483176">
<a name="2483176"></a>Olson NY, Lindsley CB. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. <i>J Rheumatol</i>. 1989;16(12):1545-1547.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/2483176/pubmed" id="2483176" target="_blank">2483176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22002012">
<a name="22002012"></a>Osadchy A, Ratnapalan T, Koren G. Ocular Toxicity in Children Exposed <i>in utero</i> to Antimalarial Drugs: Review of the Literature. <i>J Rheumatol</i>. 2011;38(12):2504-2508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/22002012/pubmed" id="22002012" target="_blank">22002012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4007043">
<a name="4007043"></a>Østensen M, Brown ND, Chiang PK, et al. Hydroxychloroquine in Human Breast Milk. <i>Eur J Clin Pharmacol</i>. 1985;28(3):357.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/4007043/pubmed" id="4007043" target="_blank">4007043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28458440">
<a name="28458440"></a>Pai SB, Sudershan B, Kuruvilla M, Kamath A, Suresh PK. Hydroxychloroquine-induced erythroderma. <i>Indian J Pharmacol</i>. 2017;49(1):132-134. doi:10.4103/0253-7613.201027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/28458440/pubmed" id="28458440" target="_blank">28458440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12224986">
<a name="12224986"></a>Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. <i>Arch Dermatol</i>. 2002;138(9):1231‐1233. doi:10.1001/archderm.138.9.1231<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/12224986/pubmed" id="12224986" target="_blank">12224986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31375884">
<a name="31375884"></a>Peng W, Liu R, Zhang L, Fu Q, Mei D, Du X. Breast milk concentration of hydroxychloroquine in Chinese lactating women with connective tissue diseases. <i>Eur J Clin Pharmacol</i>. 2019;75(11):1547-1553. doi:10.1007/s00228-019-02723-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/31375884/pubmed" id="31375884" target="_blank">31375884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32441332">
<a name="32441332"></a>Pereira A, Cruz-Melguizo S, Adrien M, Fuentes L, Marin E, Perez-Medina T. Clinical course of coronavirus disease-2019 in pregnancy. <i>Acta Obstet Gynecol Scand.</i> Published online May 22, 2020. doi:10.1111/aogs.13921<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/32441332/pubmed" id="32441332" target="_blank">32441332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31532077">
<a name="31532077"></a>Petri M, Elkhalifa M, Li J, Magder LS, Goldman DW. Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy. <i>Arthritis Rheumatol</i>. 2020b;72(3):448-453. doi:10.1002/art.41121<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/31532077/pubmed" id="31532077" target="_blank">31532077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31677989">
<a name="31677989"></a>Petri M. Pregnancy and systemic lupus erythematosus. <i>Best Pract Res Clin Obstet Gynaecol</i>. 2020a;64:24-30. doi:10.1016/j.bpobgyn.2019.09.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/31677989/pubmed" id="31677989" target="_blank">31677989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23829886">
<a name="23829886"></a>Pinho de Oliveira Ribeiro N, Rafael de Mello Schier A, Ornelas AC, Pinho de Oliveira CM, Nardi AE, Silva AC. Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs. <i>Compr Psychiatry</i>. 2013;54(8):1185‐1189. doi:10.1016/j.comppsych.2013.05.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/23829886/pubmed" id="23829886" target="_blank">23829886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Concordia.1">
<a name="Concordia.1"></a>Plaquenil (hydroxychloroquine) [prescribing information]. Dublin, Ireland: Concordia Pharmaceuticals Inc; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sanofi.1">
<a name="Sanofi.1"></a>Plaquenil (hydroxychloroquine) tablets, USP [product monograph]. Laval, Quebec, Canada: Sanofi-aventis Canada Inc; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Prystowsky.1">
<a name="Prystowsky.1"></a>Prystowsky S, Sanchez M. Cutaneous sarcoidosis: Management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 12, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21044434">
<a name="21044434"></a>Rath T, Rubbert A. Drug combinations with methotrexate to treat rheumatoid arthritis. <i>Clin Exp Rheumatol</i>. 2010;28(5)(suppl 61):S52-S57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/21044434/pubmed" id="21044434" target="_blank">21044434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30758479">
<a name="30758479"></a>Riley K, Schwager Z, Stern M, Vleugels RA, Femia A. Assessment of antimalarial therapy in patients who are hypersensitive to hydroxychloroquine. <i>JAMA Dermatol</i>. 2019;155(4):491‐493. doi:10.1001/jamadermatol.2018.5212<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/30758479/pubmed" id="30758479" target="_blank">30758479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14999113">
<a name="14999113"></a>Roden DM. Drug-induced prolongation of the QT interval. <i>N Engl J Med</i>. 2004;350(10):1013‐1022. doi:10.1056/NEJMra032426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/14999113/pubmed" id="14999113" target="_blank">14999113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol</i>. 2020;72(4):529-556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32289395">
<a name="32289395"></a>Sharma AN, Mesinkovska NA, Paravar T. Characterizing the adverse dermatologic effects of hydroxychloroquine: a systematic review. <i>J Am Acad Dermatol</i>. 2020;83(2):563-578. doi:10.1016/j.jaad.2020.04.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/32289395/pubmed" id="32289395" target="_blank">32289395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9918262">
<a name="9918262"></a>Shojania K, Koehler BE, Elliott T. Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis. <i>J Rheumatol</i>. 1999;26(1):195‐196.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/9918262/pubmed" id="9918262" target="_blank">9918262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22985607">
<a name="22985607"></a>Singal AK, Kormos-Hallberg C, Lee C, et al. Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. <i>Clin Gastroenterol Hepatol</i>. 2012;10(12):1402-1409. doi:10.1016/j.cgh.2012.08.038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/22985607/pubmed" id="22985607" target="_blank">22985607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Singal.1">
<a name="Singal.1"></a>Singal AK, Anderson KE. Porphyria cutanea tarda and hepatoerythropoietic porphyria: Management and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 19, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26545940">
<a name="26545940"></a>Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. <i>Arthritis Rheumatol</i>. 2016;68(1):1-26. doi:10.1002/art.39480<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/26545940/pubmed" id="26545940" target="_blank">26545940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27156434">
<a name="27156434"></a>Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis [published correction appears in <i>Lancet</i>. 2016;388(10055):1984]. <i>Lancet</i>. 2016;388(10055):2023-2038. doi:10.1016/S0140-6736(16)30173-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/27156434/pubmed" id="27156434" target="_blank">27156434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31969328">
<a name="31969328"></a>Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Ann Rheum Dis</i>. 2020;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/31969328/pubmed" id="31969328" target="_blank">31969328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24161836">
<a name="24161836"></a>Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Ann Rheum Dis</i>. 2014;73(3):492-509. doi:10.1136/annrheumdis-2013-204573<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/24161836/pubmed" id="24161836" target="_blank">24161836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26457932">
<a name="26457932"></a>Soria A, Barbaud A, Assier H, et al. Cutaneous adverse drug reactions with antimalarials and allergological skin tests. <i>Dermatology</i>. 2015;231(4):353‐359. doi:10.1159/000438787<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/26457932/pubmed" id="26457932" target="_blank">26457932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17590456">
<a name="17590456"></a>Stas P, Faes D, Noyens P. Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine. <i>Int J Cardiol</i>. 2008;127(2):e80‐e82. doi:10.1016/j.ijcard.2007.04.055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/17590456/pubmed" id="17590456" target="_blank">17590456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23515601">
<a name="23515601"></a>Stelton CR, Connors DB, Walia SS, Walia HS. Hydrochloroquine retinopathy: characteristic presentation with review of screening. <i>Clin Rheumatol</i>. 2013;32(6):895-898. doi:10.1007/s10067-013-2226-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/23515601/pubmed" id="23515601" target="_blank">23515601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31575325">
<a name="31575325"></a>Takamasu E, Yokogawa N, Shimada K, Sugii S. Simple dose-escalation regimen for hydroxychloroquine-induced hypersensitivity reaction in patients with systemic lupus erythematosus enabled treatment resumption. <i>Lupus</i>. 2019;28(12):1473‐1476. doi:10.1177/0961203319879987<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/31575325/pubmed" id="31575325" target="_blank">31575325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28992797">
<a name="28992797"></a>Tal Y, Maoz Segal R, Langevitz P, Kivity S, Darnizki Z, Agmon-Levin N. Hydroxychloroquine desensitization, an effective method to overcome hypersensitivity-a multicenter experience. <i>Lupus</i>. 2018;27(5):703‐707. doi:10.1177/0961203317735185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/28992797/pubmed" id="28992797" target="_blank">28992797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Targoff.1">
<a name="Targoff.1"></a>Targoff IN. Initial treatment of dermatomyositis and polymyositis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15728331">
<a name="15728331"></a>Telgt DS, van der Ven AJ, Schimmer B, Droogleever-Fortuyn HA, Sauerwein RW. Serious psychiatric symptoms after chloroquine treatment following experimental malaria infection. <i>Ann Pharmacother</i>. 2005;39(3):551‐554. doi:10.1345/aph.1E409<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/15728331/pubmed" id="15728331" target="_blank">15728331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7904547">
<a name="7904547"></a>Tett SE. Clinical pharmacokinetics of slow-acting antirheumatic drugs. <i>Clin Pharmacokinet</i>. 1993;25(5):392-407. doi:10.2165/00003088-199325050-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/7904547/pubmed" id="7904547" target="_blank">7904547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26971103">
<a name="26971103"></a>Thorbinson C, Oni L, Smith E, Midgley A, Beresford MW. Pharmacological management of childhood-onset systemic lupus erythematosus. <i>Paediatr Drugs</i>. 2016;18(3):181-195.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/26971103/pubmed" id="26971103" target="_blank">26971103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tincani.1">
<a name="Tincani.1"></a>Tincani A, Faden D, Lojacono A, et al. Hydroxychloroquine in pregnant patients with rheumatic disease. <i>Arthritis Rheum</i>. 2001;44 (Suppl 9):S397.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23716032">
<a name="23716032"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(4):479‐487. doi:10.1161/CIRCOUTCOMES.113.000152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/23716032/pubmed" id="23716032" target="_blank">23716032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24803473">
<a name="24803473"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. <i>Circ Cardiovasc Qual Outcomes</i>. 2014;7(3):381‐390. doi:10.1161/CIRCOUTCOMES.113.000651<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/24803473/pubmed" id="24803473" target="_blank">24803473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23635029">
<a name="23635029"></a>Tönnesmann E, Kandolf R, Lewalter T. Chloroquine cardiomyopathy - a review of the literature. <i>Immunopharmacol Immunotoxicol</i>. 2013;35(3):434‐442. doi:10.3109/08923973.2013.780078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/23635029/pubmed" id="23635029" target="_blank">23635029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22550010">
<a name="22550010"></a>Tönnesmann E, Stroehmann I, Kandolf R, et al. Cardiomyopathy caused by longterm treatment with chloroquine: a rare disease, or a rare diagnosis? <i>J Rheumatol</i>. 2012;39(5):1099‐1103. doi:10.3899/jrheum.110959<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/22550010/pubmed" id="22550010" target="_blank">22550010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Travassos.1">
<a name="Travassos.1"></a>Travassos M, Laufer MK. Antimalarial drugs: An overview. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 15, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26479437">
<a name="26479437"></a>Tsang-A-Sjoe MW, Bultink IE. Systemic lupus erythematosus: review of synthetic drugs. <i>Expert Opin Pharmacother</i>. 2015;16(18):2793-2806. doi:10.1517/14656566.2015.1101448<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/26479437/pubmed" id="26479437" target="_blank">26479437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23063019">
<a name="23063019"></a>Tunks RD, Clowse ME, Miller SG, Brancazio LR, Barker PC. Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents. <i>Am J Obstet Gynecol</i>. 2013;208(1):64.e1-64.e647. doi:10.1016/j.ajog.2012.09.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/23063019/pubmed" id="23063019" target="_blank">23063019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21169846">
<a name="21169846"></a>Unübol M, Ayhan M, Guney E. Hypoglycemia induced by hydroxychloroquine in a patient treated for rheumatoid arthritis. <i>J Clin Rheumatol</i>. 2011; 17(1):46-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/21169846 /pubmed" id="21169846 " target="_blank">21169846 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vleugels.1">
<a name="Vleugels.1"></a>Vleugels RA. Cutaneous dermatomyositis in adults: Overview and initial management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 21, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17952481">
<a name="17952481"></a>Volpe A, Marchetta A, Caramaschi P, Biasi D, Bambara LM, Arcaro G. Hydroxychloroquine-induced DRESS syndrome. <i>Clin Rheumatol</i>. 2008;27(4):537‐539. doi:10.1007/s10067-007-0772-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/17952481/pubmed" id="17952481" target="_blank">17952481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wallace.1">
<a name="Wallace.1"></a>Wallace DJ. Antimalarial drugs in the treatment of rheumatic disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 25, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10229401">
<a name="10229401"></a>Wang C, Fortin PR, Li Y, Panaritis T, Gans M, Esdaile JM. Discontinuation of antimalarial drugs in systemic lupus erythematosus. <i>J Rheumatol</i>. 1999;26(4):808‐815.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/10229401/pubmed" id="10229401" target="_blank">10229401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34087822">
<a name="34087822"></a>Wang G, Zhuo N, Liao Z, et al. Retinal toxicity caused by hydroxychloroquine in patients with systemic lupus erythematosus: a case report. <i>Medicine (Baltimore)</i>. 2021;100(22):e25688. doi:10.1097/MD.0000000000025688<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/34087822/pubmed" id="34087822" target="_blank">34087822</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11508449">
<a name="11508449"></a>Warner AE. Early hydroxychloroquine macular toxicity. <i>Arthritis Rheum</i>. 2001;44(8):1959-1961. doi:10.1002/1529-0131(200108)44:8&lt;1959::AID-ART334&gt;3.0.CO;2-A<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/11508449/pubmed" id="11508449" target="_blank">11508449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30140893">
<a name="30140893"></a>Wolstencroft PW, Casciola-Rosen L, Fiorentino DF. Association between autoantibody phenotype and cutaneous adverse reactions to hydroxychloroquine in dermatomyositis. <i>JAMA Dermatol</i>. 2018;154(10):1199‐1203. doi:10.1001/jamadermatol.2018.2549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/30140893/pubmed" id="30140893" target="_blank">30140893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). <i>Guidelines for the Treatment of Malaria</i>. 3rd ed. Geneva, Switzerland: World Health Organization; April 2015. https://apps.who.int/iris/bitstream/handle/10665/162441/9789241549127_eng.pdf;jsessionid=5E6B69DD1F9A124C2DFEA30D5F8D6E8E?sequence=1. Accessed August 15, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). International travel and health. World Health Organization; 2012. Available at https://www.who.int/publications/i/item/9789241580472
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2017">
<a name="WHO.2017"></a>World Health Organization (WHO). <i>The cardiotoxicity of antimalarials</i>. Geneva, Switzerland: World Health Organization; March 2017. https://www.who.int/malaria/mpac/mpac-mar2017-erg-cardiotoxicity-report-session2.pdf. Accessed May 26, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6715608">
<a name="6715608"></a>Woo TY, Callen JP, Voorhees JJ, Bickers DR, Hanno R, Hawkins C. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. <i>J Am Acad Dermatol</i>. 1984;10(4):592-600. doi: 10.1016/s0190-9622(84)80263-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/6715608/pubmed" id="6715608" target="_blank">6715608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20701405">
<a name="20701405"></a>Youngster I, Arcavi L, Schechmaster R, et al. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. <i>Drug Saf.</i> 2010;33(9):713-726. doi:10.2165/11536520-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxychloroquine-drug-information/abstract-text/20701405/pubmed" id="20701405" target="_blank">20701405</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8541 Version 558.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
